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Metastasis is one of the critical hallmarks of malignancy tumor and the principal 
cause of death in patients with cancer. Cell migration is the basic and essential step in 
cancer metastasis process. To systematically investigate functional genes regulating 
cell migration and cancer metastasis on large scale, we developed a novel on-chip 
method, SAMcell (self-assembled cell microarray). This method was demonstrated to 
be particularly suitable for loss-of-function high-throughput screening because of its 
unique advantages. The first application of SAMcell was to screen human genome 
miRNAs, considering that more and more miRNAs had been proved to govern cancer 
metastasis. We found that over 20 % of miRNAs have migratory regulation activity in 
diverse cell types, indicating a general involvement of miRNAs in migratory 
regulation. Through triple-round screenings, we discovered miR-23b, which is 
down-regulated in human colon cancer samples, potently mediates the multiple steps 
of metastasis, including cell motility, cell growth and cell survival. In parallel, the 
second application of SAMcell was to screen human genome kinase genes, 
considering that more and more kinase genes had become successful diagnostic 
marker or drug targets. We found over 11% migratory kinase genes, suggesting the 
important role of kinase group in metastasis regulation. Through both functional 
screening and bioinformatics analysis, we discovered and validated 6 prospective 
metastasis-related kinase genes, which can be new potential targets in cancer therapy. 
These findings allow the understanding of regulation mechanism in human cancer 
progression, especially metastasis and provide the new insight into the biological and 
therapeutical importance of miRNAs or kinases in cancer.   
  
Key Words: Cancer metastasis; High-throughput screening; SAMcell; 




CHAPTER 1                                
INTRODUCTION 
 
1.1 Cancer metastasis 
 
Metastasis is one of the critical hallmarks of malignancy tumor and the principal cause 
of death in patients with cancer[1]. By now, statistical data indicate that metastases 
account for 90% of human cancer deaths[2]. However, our understanding of the 
molecular circuitry that regulates metastatic dissemination remains obscure. The 
knowledge of detailed metastasis mechanisms may lead to promising opportunities for 
drug discovery and clinical therapy in cancer treatment[3].  
 
1.1.1 The metastasis cascade 
 
Metastasis, or metastatic disease, is the spread of a cancer from one organ or part to 
another non-adjacent organ or part[4]. It was previously thought that only malignant 
tumor cells and infections have the capacity of metastasis; however, this has been 
reconsidered due to the discovery that normal mammary epithelial cells may establish 
residence in the lung once they have entered the bloodstream circulation and may 
assume malignant growth once oncogene activation[5]. Cancer metastasis is a 
complex and multi-step process. First of all, cells at the tumor edge break away from 
the primary tumor and locally migrate into neighboring ECMs (extracellular matrix). 
Secondly, cancer cells invade into the adjacent tissues. Thirdly, some cancer cells 
acquire the ability to penetrate the walls of lymphatic or blood vessels, after which 
they are able to circulate and survive during bloodstreams. Next, cancer cells are 
arrested at distant site and extravasate to reach foreign tissue parenchyma. Finally, 
2 
 
they proliferate from microscopic growth into macroscopic secondary tumor.[6]  
 
1.1.2 Cell migration involving in metastasis 
 
Cell migration refers to the translation of cells from one location to another. Cells 
often migrate in response to specific external signals, including chemical signals 
and mechanical signals.[7] Migration process begins with polarization to form 
protrusion at the front and constriction at the rear, then the tail detaches and contracts 
to generate a movement[8].  
 
Cell migration plays a central role in the development and maintenance of biological 
processes, especially metastasis. Human cells exhibit three kinds of motion, such as 
collective motility, mesenchymal-type movement, and amoeboid movement. Cancer 
cells can opportunistically switch between different kinds of motion.[9] Metastasis 
process requires a strong adaptability of cells to the different microenvironments, such 
as within primary tumors, in the ECM, in blood or lymphatic streams and finally in 
the metastatic niche. Cells in the core of the tumor mainly move using a 
mesenchymal-type movement, while cells at the tumor edge escape the tumor limit 
and enter the ECM using an amoeboid motility.[10]  
 
1.2 RNA interference technology 
 
The central tool we used is RNA interference (RNAi) technology to operate gene’s 
expression and study gene’s function. RNAi is a biological process in which RNA 
molecules inhibit gene expression, typically by resulting in the degradation of 
messenger RNA (mRNA) molecules with specific sequences. In 2006, Andrew Fire 
and Craig C. Mello shared the Nobel Prize in Physiology or Medicine for their work 
“Discovery of RNA interference - gene silencing by double-stranded RNA” on RNA 
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interference in the nematode worm C. elegans[11]. There are two types of small 
ribonucleic acid (RNA) molecules which play central roles in RNAi process, 
including microRNA (miRNA) and small interfering RNA (siRNA). According to the 
central dogma, RNA transcripts are the direct products of genes, and mRNAs guide 
the protein translation[12]. These small RNAs can bind to specific mRNA molecules 
and usually decrease their activity, either by causing cleavage of mRNAs, or by 
preventing mRNAs from producing proteins[13].  
 
1.2.1 Biogenesis and mechanism of miRNA 
 
Majority of primary microRNA( pri-miRNA) transcripts are typically produced by 
RNA Polymerase Ⅱ[14, 15]. The length of these pri-miRNAs is from hundreds to 
thousands of nucleotides with one or more double-stranded regions. Some 
pri-miRNAs have independent transcriptional unite with mono-(e.g. miR-21[16]) or 
polycistronic miRNA-precursor structure (e.g.the miR-17-92-1 cluster[17]), whereas 
others locate in the intron (e.g. miR-10b[18]) or exon (e.g. miR-198[16]) of 
messenger RNAs (mRNAs). These polymerase Ⅱ-directed pri-miRNAs are 
post-transcriptionally polyadenylated and capped at 5’end and 3’end respectively. 
However, recent data indicate that a subset of miRNAs may be transcribed by RNA 
Polymerase Ⅲ, instead of RNA Polymerase Ⅱ, such as the largest human miRNA 
cluster, C19MC[19]. Expression of individual miRNA is controlled by transcription 
factors, for example c-MYC or P53[20, 21] or lies on the methylation of promoter 
region. However, the regulatory mechanism of miRNAs at the transcriptional level is 
various. 
 
Next, the pri-miRNA is cleaved by a complex of RNase Ⅲ endonuclease Drosha and 
the DGCR8 protein (also known as Pasha)[22] which contain two double-stranded 
RNA-binding domains[23-26]. First, the DGCR8 directly interacts with the 
pri-miRNA and determines the accurate cleavage site, and then the Drosha finish the 
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cleavage processing. Consequently, an imperfect stem-loop structure of ~50-70 nt in 
length is released, with a hairpin stem, a terminal loop and two single-stranded 
flanking regions, which is named precursor microRNA (pre-miRNA). The 
double-stranded stem and the flanking regions are indispensable for DGCR8 binding 
and Drosha cleavage, in contrast, the loop region is less critical for this step[27-29]. 
 
After nuclear processing，The pre-miRNAs are transported to the cytoplasm by the 
nucleocytoplasmic shuttle Exportin-5, which recognizes a two-nucleotide overhang 
left by the RNase III enzyme Drosha at the 3' end of the pre-miRNA hairpin, rather 
than its sequence or the loop structure. Exportin-5-mediated transport to the 
cytoplasm is energy-dependent, using GTP bound to the Ran protein[30]. In the 
nuclear, with the help of high concentration of RanGTP, the Exportin-5 induces the 
Drosha complex to release pre-miRNA, and transport them off nuclear. Oppositely, in 
the cytoplasm, the low concentration of RanGTP results in the pre-miRNA being 
separated from Exportin-5. During the subsequent processing, the RNase Ⅲ 
enzyme-Dicer is in charge of cutting off the loop portion of the hairpin structure and 
yielding ~22nt small RNA duplexes consisting of the mature miRNA and a partially 
complementary strand. Knockout Dicer leads to a decreased or abrogates amount of 
mature miRNAs, which demonstrate this cleavage is essential for miRNA biogenesis 
processing[31-34]. Dicer cleavage activity is regulated by binding its amino-terminal 
DExD/H-box helicase domain to TRBP which activates Dicer through a 
conformational rearrangement[35]. 
 
Besides of canonical miRNA biogenesis pathway, several alternative pathway has 
been discovered. For example, many Drosha/DGCR8- independent pathways can 
generate pre-miRNA-like hairpin structure, which serve as Dicer substrate without 
cleaving by Drosha/DGCR8 complex (e.g. miR-62, mirR-1071) [36-39]. Additionally, 
pri-miR-451 is processing by Drosha/DGCR8 to format a short pre-miRNA with 
only~18nt of duplex stem, which is too short to recognize by Dicer. Instead, 




After the finial miRNA duplex was generated, one strand was loaded into a protein 
complex called RNA induced silencing complex (RISC)[43]. This strand is the mature 
miRNA (named guide strand), while the other strand (named passenger strand) gets 
degraded by cleavage or a bypass mechanism. An essential core protein in RISC is the 
argonaute protein (Ago), which has four related members in human. Typically, the 
mature RISCs bind to 3’UTR (untranslated regions) of mRNAs containing a partially 




 nt of the 
mature miRNA). If the seed region of miRNA can anneal with the mRNA, RISC 
cleave the mRNA or suppresses the translation without affecting the mRNA 
transcriptional level.  
 
1.2.2 RNAi high-throughput screening 
 
According to the specific sequence of mRNA from a gene, we can selectively design 
and synthesize exogenous siRNA duplex with specificity. By introducing siRNA 
duplex into either cultured cells or living organisms, the gene expression can be 
suppressed robustly. RNAi has now become a valuable research tool, especially used 
for large-scale screening to identify the components necessary for a particular cellular 
process or an event such as cell migration and cell proliferation[44, 45], by 
systematically knocking down each gene in the cell. This method is also used as a 
practical tool in biotechnology and medicine.  
 
The RNAi high-throughput screening (HTS) technology allows genome-wide 
loss-of-function screening and is broadly used to identify genes associated with 
specific biological phenotypes[46]. This technology has been hailed as the second 
genomics wave, following the first genomics wave of gene expression microarray and 
single nucleotide polymorphism (SNP) platforms[46]. One of the major advantages of 
the RNAi HTS technology is the ability to simultaneously test thousands of genes, 
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which lead to an explosion in the rate of generating data. Consequently, one of the 
most fundamental challenges in the RNAi HTS studies is to glean biological 
significance from huge scale of data, which requires the adoption of appropriate 
statistical and bioinformatics methods[47]. We can divide the analytic process of a 
cell-based RNAi screening into several steps[47]. First of all, we should choose the 
suitable RNAi library, including the vector and the gene range. Secondly, we should 
select the robust and stable type of cells. Thirdly, we should use the perfect 
transfection methods or reagents to introduce the RNAi library into cells. Fourthly, we 
should implement the necessary experimental treatment and signal detection. Finally, 
we should figure out the determination of important genes or therapeutical targets by 
statistical and bioinformatics analysis. 
 
1.3 miRNAs governing cancer metastasis 
 
miRNAs are post-transcriptional regulators that bind to complementary sequences on 
target mRNA transcripts, usually resulting in translational repression or target 
degradation and gene silencing[48, 49]. The human genome may encode over 1000 
miRNAs[50], which may target about 60% of mammalian genes[51, 52] and are 
abundant in many human cell types[53]. As a new class of signalling modulators, 
miRNAs have attracted great attention for certain unique features, including 
multi-target regulation, tissue specificity, and evolutionary conservation[54-56]. These 
small endogenous RNAs are able to interact with many physiologically essential 
genes, such as c-MYC, P53 and RAS, and play critical roles in a wide range of 
biological processes, including cell development, cell proliferation and differentiation, 
as well as cell migration and cancer metastasis[20, 21, 57, 58]. Strikingly, these 
important modulators are globally dysregulated in human cancer samples[59]. A small 
number of miRNAs have been demonstrated to actively participate in the regulation 
of tumor development[60-64]. With the latest deciphering of roles for miRNAs in the 
metastatic progress, there are new hopes that we can interpret the molecular pathways 
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underlying each step through miRNAs. Since miRNAs were involved in cancer 
pathogenesis[65], accumulating data have pointed to a central regulatory role for 
miRNAs in the initiation and progression of most cancers analyzed thus far[64].   
 
1.3.1 miRNA as metastasis activator 
 
In Weinberg’s group, using a combination of mouse and human cells, they showed 
that miR-10b is highly expressed in metastatic breast cancer cells and positively 
regulates cell migration and invasion[62]. Importantly, over-expression of this 
miR-10b in otherwise non-metastatic breast cancer cells enables them to acquire 
invasive and metastatic capability. Expression of miR-10b is induced by the 
transcription factor TWIST, which binds directly to the putative promoter of mir-10b, 
and is essential for TWIST induced epithelial–mesenchymal transition (EMT) that 
promotes cell motility[66]. The miR-10b induced by TWIST binds directly to mRNA 
of HOXD10 and represses translation of HOXD10, resulting in up-regulated 
expression of a famous pro-metastatic gene, RHOC. Significantly, the level of 
miR-10b expression in primary breast carcinomas correlates with clinical 
progression6. These findings suggest an undescribed signalling pathway, in which a 
pleiotropic transcription factor (TWIST) induces expression of a specific miRNA 
(miR-10b), which suppresses its direct target (HOXD10) and activates another 
pro-metastatic gene (RHOC), leading to cell invasion and tumor metastasis. 
 
In a collaborative effort between Huang and Agami’s groups, to identify potential 
metastasis promoting miRNAs, through a genetic screen using a nonmetastatic, 
human breast tumor cell line that was transduced with a miRNA-expression library 
and subjected to a trans-well migration assay, miR-373 and miR-520c were also 
identified as metastasis promoting genes[61]. In MCF7 breast cancer cells, 
over-expression of miR-373 or miR-520c promoted an in vitro migration and invasion. 
Furthermore, nude mice transplanted with these cells induced metastatic nodules, 
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whereas control cells did not. miR-373 and miR-520c were found to share a similar 
‘seed’ sequence and to have a common direct target CD44, which encodes a cell 
surface receptor for hyaluronan. CD44 is lost in breast cancer with high metastatic 
potential and acts as a metastatic suppressor in also prostate and colon cancer. It was 
found that significant up-regulation of miR-373 in clinical breast cancer metastasis 
samples that correlated inversely with CD44 expression[61].  
 
According to the study of Ma and colleagues, the research reveal that miR-9 is 
up-regulated in breast cancer cells, directly targets CDH1, the E-cadherin-encoding 
messenger RNA, leading to increased cell motility and invasiveness[67]. 
miR-9-regulated E-cadherin down expression induces the activation of β-catenin 
signaling pathway, which results in up expression of the gene encoding VEGF, which 
leads to tumor angiogenesis. miR-9 is positively associated with malignancy of 
human cancers. miR-9 expression is significantly up-regulated in both clinical breast 
cancers[68] and in c-myc-induced mouse mammary tumors[69]. Conversely, 
inhibiting miR-9 expression in highly malignant cells inhibits metastasic capability. 
MYC and MYCN oncoproteins, acting on the mir-9-3 locus, activate miR-9 
expression in tumor cells. Significantly, in human cancers, miR-9 levels correlate with 
MYCN amplification, tumor grade and metastatic status[67].  
 
1.3.2 miRNA as metastasis suppressor 
 
HMGA2, a member of the high mobility group AT-hook family of nonhistone 
chromatin proteins, is an architectural transcription factor[70], which plays a critical 
role in growth during embryonic development[71]. Knockdown of Dicer in HeLa 
cells revealed that the HMGA2 gene is transcriptionally active, but its mRNA is 
destabilized in the cytoplasm through the miRNA pathway[72]. HMGA2 was 
repressed by let-7 in cells. Ectopic expression of miRNA let-7 down regulates 
HMGA2 and cell proliferation in lung cancer cells through directly binds to the target 
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sites in the 3’ untranslated region (UTR). At the same time, The 3’ UTR of the human 
RAS gene, which is also a famous oncogene, contains multiple complementary sites, 
allowing let-7 to regulate RAS expression[58]. let-7 expression is lower in lung 
tumors than in normal lung tissue, while RAS protein is significantly higher in lung 
tumors. These findings suggest that let-7 can serve as a tumor suppressor gene 
through inhibiting the expression of oncogenes HMGA2 and RAS.  
  
Weinberg’s group identified an antimetastatic human miRNA, miR-31, that acts at 
multiple steps of the invasion-metastasis cascade via repression of a cohort of 
prometastatic targets[73]. Genome-wide studies have described miR-31 
down-regulation or deletion of the miR-31 genomic locus in human breast cancers[74, 
75]. miR-31 represses metastasis without contributing to influence on primary tumor 
development. As such, mir-31 might aptly be categorized as a ‘metastasis suppressor 
gene’[76]. Of significance, down regulation of miR-31 enhances migration, invasion, 
and anoikis resistance in human breast epithelial cancer cells. Conversely, increasing 
expression of miR-31 reduces migratory, invasive and metastasic capability both in 
vitro and in vivo and represses EMT markedly. The direct targets of miR-31 are Fzd3, 
ITGA5, MMP16, RDX, and RhoA, which are famous pro-metastasic proteins 
described in human tumors[77-79]. miR-31 expression was diminished in primary 
tumors that subsequently metastasized, when compared to normal breast tissue and 
primary tumors that did not recur; moreover, low miR-31 levels correlated strongly 
with reduced distant disease-free survival relative to tumors with high miR-31[78]. 
This suggests one putative mechanism by which the invasion-metastasis cascade 
could be initiated very early during the course of tumor progression, a phenomenon 
that has recently been observed in clinical breast tumors[80]. 
 
1.3.3 miRNA involved in EMT  
 
Epithelial-mesenchymal transition (EMT) describes a reversible series of events 
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during which an epithelial cell loses cell-cell contacts and acquires mesenchymal 
characteristics. These events involve molecular reprogramming of the cell, including 
loss or redistribution of epithelial-specific junctional proteins such as E-cadherin and 
turning on of mesenchymal markers including vimentin and N-cadherin[81]. The 
embryonic programme ‘epithelial–mesenchymal transition’ (EMT) is thought to 
promote malignant tumor progression[82]. EMT induces detachment of cells from 
each other and increasing cell mobility, both of which are necessary for tumor cell 
dissemination. Metastases often contain the differentiated phenotype of the primary 
tumor; therefore, EMT seems to be activated by the invasive tumor environment, but 
is reversed in growing metastases[83]. Activators of EMT, such as TGFβ, TNFα and 
HGF, are produced by penetrating cells or the tumor cells themselves, and enhance 
expression of EMT transcriptional repressors[81], including the Snail family, the 
basic helix–loop–helix family, Goosecoid and members of the ZFH family, ZEB1 and 
ZEB2[84, 85]. ZEB is a crucial inducer of EMT in various human tumors, and was 
recently shown to promote invasion and metastasis of tumor cells.  
 
Goodall’s group and others shown that the miR-200 family is down regulated in 
metaplastic and basal breast cancers respectively, relative to ductal breast tumors[86, 
87]. These differences most likely reflect the more poorly differentiated grade of these 
tumors compared to ductal tumors, and in the case of metaplastic tumors are 
indicative of EMT-like changes having taken place as observed in their characteristic 
sarcomatoid (mesenchymal) morphology and expression profile[77, 87]. These 
findings indicate miR-200 family participates in a signalling network with the 
E-cadherin transcriptional repressors ZEB, and TGFβ2. In fact, miR-200 family 
directly binds to mRNAs of ZEB1 and ZEB2 and represses the translation process.  
 
Interestingly, Thomas Brabletz’s group reported that ZEB1 directly suppresses 
transcription of microRNA-200 family members miR-141 and miR-200c, by binding 
to at least two highly conserved sites in their putative promoter, which strongly 
activate epithelial differentiation in pancreatic, colorectal and breast cancer cells[86]. 
11 
 
Notably, as above, the EMT activators TGFβ2 and ZEB1 are the predominant targets 
down-regulated by these microRNAs. These results indicate that ZEB1 induces a 
miRNA-mediated feed forward loop that stabilizes EMT and promotes invasion and 
metastasis of cancer cells.  
1.4 Protein kinase modulating cancer metastasis 
 
Protein kinase is involved extensively in transmitting signals and controlling complex 
processes in cells. More than five hundred different kinases have been identified in 
humans and they constitute about 2% of all human genes.[88] Recent data have 
pointed to a central regulatory role of kinase genes in cell migration and cancer 
mestastasis. For example, PI-3-kinase and MAPK regulate cell proliferation and 
migration in response to PDGF[89]. FAK functions as a key regulator of fibronectin 
receptor stimulated cell migration events through the recruitment of both SH2 and 
SH3 domain containing signaling proteins to sites of integrin receptor clustering[90]. 
However, comprehensive understanding of kinases’ function involved in cancer 
metastasis is essential for drug discovery and clinical medicine.  
 
1.4.1 Protein kinase as biomarker for diagnosis 
 
The ERBB2 (another name is HER2) oncogene is a member of the erbb-like oncogene 
family, and is related to, but distinct from, the epidermal growth factor receptor[91]. 
This gene was found to be amplified from 2- to more than 20-fold in 30% of the 
tumors[92]. Correlations between gene amplification and several disease parameters 
were evaluated, hence expression level of ERBB2 was a significant predictor of both 
survival and relapse in patients with breast cancer[93]. Recent studies highlighted the 
distinguishing status between primary tumor and metastatic sites, with a discordance 
rate of 10–17.5%[94]. This gene plays an important role in both biology behavior and 




1.4.2 Protein kinase as drug target for therapy 
 
ROCK1 and ROCK2 support the metastatic growth of a spectrum of human cancer 
types, making them potential targets for the development of antitumor drugs[95]. 
ROCK is activated in cancer when bound to the GTP-bound form of Rho GTPase. 
Recently, Sebti’s group reported on the design and synthesis of novel Rho-kinase 
inhibitors (RKIs), using a fragment-based approach and X-ray crystallography[96]. 
They selected several RKIs to test in cancer and found that inhibition of ROCK1 with 
RKI-18 results in preventing migration, invasion and anchorage-independent growth. 
Virtually, protein kinase has now become the second most important group 
of drug targets[97].  
 
1.5 Research approaches for migratory genes 
 
Usually, research of cancer metastasis begins with investigation of cell migratory 
behavior. However, the traditional methods for cell migration studies, such as wound 
healing assay or Transwell assay, cannot be scaled up for high-throughput screening 
easily. So the motivation of next generation HTS is to create an on-chip approach. 
 
1.5.1 Conventional migration assays 
 
The wound healing assay is an easy, low-cost and well-developed method to measure 
cell migration in vitro[98]. The basic step is to create a ‘‘scratch’’ in a cell monolayer, 
capturing the images at different times during cell migration to close the scratch, and 
comparing the images to calculate the migration rate of the cells[99]. 
The Transwell assay, originally introduced by Boyden for the analysis of leukocyte 
chemotaxis, is based on a chamber of two medium-filled compartments separated by a 
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microporous membrane[100]. In general, cells are placed in the upper chamber and 
are allowed to migrate through the pores of the membrane into the lower chamber, in 
which chemotactic agents are present. After an appropriate incubation time, the 
number of cells that have migrated to the lower side of the membrane is determined.   
 
1.5.2 HTS assays for identification of migratory genes 
 
Recently, several groups have focused on developing a new approach. Simpson 
created a robotic-driven pin to deliver a precise scratch in confluent cell monolayers 
to perform a wound healing screen with MCF-10A breast epithelial cells[44]. This 
method demands specific equipments, yet the boundaries of the edges generated by 
the bins are not clear enough. This results in poor veracity and big error.  
 
Miyake’s idea of printing both the labeled fibronectin, for identification of the starting 
region of a cell, and the green fluorescent protein (GFP) expression vector, for 
identification of cells that had been transfected with miRNA and of the end point of 
migration, brings a rapid and efficient high-throughput screening procedure[3]. This 
approach requires peculiar cell line, and diffusion of cells will bring out remarkable 
cross-contamination. Furthermore, the signals are not propitious to statistically 
analysis.  
 
Agami set up a genetic screen using a nonmetastatic, human breast tumor cell line that 
was transduced with a miRNA-expression library and subjected to a transwell 
migration assay[61]. This is an excellent idea. However, a blemish in an otherwise 
perfect thing lies that the results just contain migration-promoting miRNAs but 
without migration-suppressing miRNAs. Although these methods have improved 
experimental throughput to a certain degree, they are still either technically 
demanding or only applicable to specific cell lines, thus hampering their application to 




1.6 Problem statement and content of this thesis 
 
By far, we have two central problems: how to systematically investigate functional 
genes regulating cancer metastasis and how to identify genes which play central roles 
and can be potential targets of cancer therapy. To address these questions, we should 
develop a new HTS assay suitable to study cancer cell behaviors, especially migration 
and make sure the determination of important genes and therapeutical targets.  
 
At first, we developed a novel method, SAMcell (self-assembled cell microarray), for 
investigation of cell migration behaviors on large scale. The current assays are not 
suitable for HTS. And there is no previous report that HTS was performed through an 
on-chip approach to investigate functional genes regulating cancer. Based on SAMcell, 
we also set up a pipelining of HTS platform integrated with high-throughput devices.  
  
The first application of SAMcell based HTS system was to screen human genome 
miRNAs regulating cancer metastasis, considering that more and more miRNAs had 
been proved to govern cancer metastasis. According to what we are informed, there 
was no previous report that so many miRNAs were investigated through such a 
systematic screen. We found 20% migratory miRNAs out of more than 900 human 
miRNAs. Before our research, no evidence can help us make an overall judgment of 
migratory miRNA distribution and no research can identify so many functional genes 
at one time. In the traditional screening strategy, researchers picked up the most 
significant gene after one-round screening. But in our study, we performed 
triple-round screenings for three phenotypes and picked up the powerful gene 
miR-23b based on its performances in three rounds of screenings.  
 
In parallel, the second application of SAMcell based HTS system was to screen 
human genome kinase genes regulating cancer metastasis, considering that more and 
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more kinase genes had become successful diagnostic marker or drug targets. There 
was no previous research that focused on the group of kinase and performed both 
functional screening and bioinformatics analysis for functional genes regulating 
cancer metastasis. We found 11% migratory genes out of more than 700 human 





CHAPTER 2                                   
DEVELOPMENT OF SELF-ASSEMBLED CELL MICROARRAY 
 
2.1 Fabrication of SAMcell 
 
We developed a self-assembled cell microarray (SAMcell) to examine the capacity of 
miRNA or siRNA to mediate cell migration. The fabrication of a self-assembled cell 
microarray is schematically shown in Figure 2.1a. Glass slides (2.5 cm × 2.5 cm) were 
washed with detergent and miliQ water. After dryness, the slides were covered with 
Poly (N-isopropylacrylamide) (For short PNI, Aldrich) dissolved in ethanol (6 % w/v). 
The slides were etched via a shadow mask by oxygen plasma for 5 min at 200 w 
Power. The protocol refers to previous description[101]. In brief, 3 μl of OptiMEM 
(Invitrogen), containing sucrose and 2.5 μl LipofectamineTM 2000 (Invitrogen) were 
transferred to each tube and mixed thoroughly. Then, 2 μg siRNA/ 1 μg plasmid was 
added to each tube and the mixture was incubated for 20 min at room temperature. 
Finally, 7.25 μl of a 0.2 % (w/v) gelatin (Sigma, Type B) solution was added to each 
tube and mixed thoroughly. After UV sterilization, the reverse transfection reagent 
was printed on the chip via nanodispenser (Phoenix, Art Robbins Instruments, US). 
Next, the slides were fixed in a 6-well plate by melted wax. About 3 ml 37 °C 
medium containing 5 × 10
5
 cells were transferred in each well. Cells self-assembled 
within each circle, since they grew very well on the glass slide, but rather poorly on 
PNI. PNI has been previously demonstrated to have a sharply lower critical solution 
temperature, ~32 °C [102]. That is, PNI undergoes a solid–liquid phase transition as it 
is cooled below 32 °C, and dissolves in the surrounding aqueous medium. About 
24-48 h later, the dishes were moved at room temperature for 5 min and washed with 
PBS for three times to ensure the total removal of the polymer. Therefore, the 
subsequent removal of the dissolved polymer results in the formation of individual 
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cell islands, enabling them to acquire the freedom to move. Cell chips were recorded 
by a microscope system (Image Xpress, Molecular Devices, US). Areas of cell islands 
were measured by the software of Image J. Polygon selections were used to recognize 
the boundary of cells, and both Analyze and Measure were used to calculate the area 
of the islands. Four repeats were performed in each group.   
 
By now, we set up a SAMcell based pipelining for RNAi high-throughput screening 
(Figure 2.1b). To detect the transfection efficiency and cross-contamination of this 
method, we alternatively printed GFP (Green Fluorescent Protein) expressing plasmid 
and NC (negative control) plasmid in an array of 10 by 10 on one chip. We addressed 
the issue of cross-contamination by adjusting the size and number of siRNA spots 
prior to large-scale screening. When a circle had a diameter of approximately 800 μm 
and its center-center distance was no less than 2.25 mm, no detectable 
cross-contamination was observed on our chip (Figure 2.1c).  
 
 
Figure 2.1 Self-assembled cell microarray  
a. Fabrication of the self-assembled cell microarray (SAMcell). 
b. Pipelining of SAMcell based high-throughput screening. Scale bar: 500 μm. 
c. No detectable cross-contamination in neighbouring diagonal positions. GFP 
expressing plasmid and NC plasmid were alternatively spotted on 10 X 10 arrays in 
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the microarray. Schematic diagram and fluorescent microscopic images are shown in 
the left and right panels, respectively. Scale bar: 500 μm. 
 
2.2 SAMcell studying cell migration 
 
We first investigated the capacity of this microarray to effectively detect cell 
migration. To minimize the effect of cell proliferation on migration, we did not 
remove PNI until the cells within a given island had become confluent. The data 
showed that within a certain period, such as 9 hours, the island area increased as a 
linear function of time, so that the slopes could represent the migratory activities, at 
least for the three cell lines Hela, HepG2, U2OS (Figure 2.2a). Given the facts that 
PNI patterns were micro-fabricated on the basis of semiconductor technology and that 
the self-assembled cell islands were incubated under the same culture conditions, this 
assay demonstrates clear advantages in reliability and accuracy over the traditional 
scratch wound healing assays. Five parallel experiments resulted in no more than a 
5 % standard deviation for each cell line (Figure 2.2b).  
 
Next, we synthesized a number of siRNAs, each targeting PTEN, RHOG or SGEF, as 
well as a scrambled siRNA as negative control, and then printed them on a glass slide. 
The quantitative real-time PCR results validated the silencing efficiency of these 
siRNAs (Figure 2.2c). As expected, the assay showed that both Hela and U2OS cells 
moved faster when PTEN was silenced, whereas both cell types migrated more slowly 
when either RHOG or SGEF was inhibited (Figure 2.2d)[103, 104]. Therefore, 
through the incorporation of RNAi technology, this microarrary is applicable to 





Figure 2.2 The study of cell migration by use of SAMcell  
a. The self-assembled cell microarray was applied to study the migration of three 
types of cells, Hela (green), HepG2 (blue) and U2OS (red). 
b. Reliability of the microarray. The migration speed referred to the ratio of island 
area to time. All speeds were normalized to Hela. n = 5. 
c. Real-time PCR results showed that PTEN, RHOG and SGEF could be efficiently 
silenced by the corresponding siRNAs in Hela (left) or U2OS cells (right), 
respectively. GAPDH was used as an internal quantification control, and scrambled 
siRNA as NC. n=3. 
d. Cell migration was examined when various genes were silenced in Hela (left) or 
U2OS cells (right), respectively. n =5. 
 
2.3 Statistical preparation for HTS 
 
We first concluded a formula to calculate the cell island’s migration speed, MS= 
(Af-Ai)/T , where Af is the final area, Ai is the initial area, and T is the time of the 
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process. The migration speed treated with one specific siRNA/miRNA was 
normalized to that treated with scrambled siRNA which played as the negative control. 
Consequently, we could use the fold change, which is equal to the normalized 
migration speed, to represent the migratory activity influenced by siRNAs/miRNAs. 
 
Then we printed 40 repeats of scrambled siRNAs in parallel on one chip to calculate 
the fold changes of cell migration and drew the frequency histogram (Figure 2.3a). 
Range of fold change is from 0.9 to 1.1, so cut-off for SAMcell migration assay is 
<0.9 or >1.1. To determine whether data sets come from normal distribution, we used 
Shapiro-Wilk W-test and Kolmogorov–Smirnov Z-test (JMP9.0 Software), with the 
null hypothesis that the sample came from a normally distributed population. 
P(W)=0.854, P(Z)=0.978. The possibilities were so big that we could accept the null 
hypothesis. That is, the distribution of population was closed to normal distribution.  
 
Similarly, we examined the distributions of the datasets from Transwell migration 
assay and Transwell invasion assay. We also performed 40 repeats of scrambled 
siRNAs in parallel and drew the frequency histograms (Figure 2.3b and c). After 
W-test and Z-test, they were closed to normal distribution. However, the ranges of 
fold change from both Transwell assays are from 0.8 to 1.2, so cut-off for Transwell 
migration/invasion assay is <0.8 or >1.2. 
 
When comparing two groups, we took use of unpaired Student's t-tests (two-tailed) to 
calculate the significance. For all tests, a P value <0.05 was considered significant. 






Figure 2.3 Frequency histograms of three assays. 
a. SAMcell migration assay. P(W)=0.854, P(Z)=0.978. Range of fold change is from 
0.9 to 1.1.  
b. Transwell migration assay. P(W)=0.596, P(Z)=0.984. Range of fold change is from 
0.8 to 1.2. 
c. Transwell invasion assay. P(W)=0.596, P(Z)=0.984. Range of fold change is from 
0.8 to 1.2. 
 
2.4 Summary of SAMcell method 
 
In order to perform the migration screening on a large-scale level, we developed a 
self-assembled cell microarray. Compared to the traditional Transwell assay and 
wound healing assay, this method demonstrates certain important advantages, 
including lower cost of transfection reagents, RNAs, antibodies or dyes, higher 
throughput and more reliable accuracy. Due to a thermally responsive polymer, this 
microarray has additional important features, such as tailored cell patterns, as well as 
a clear cell boundary and hence no interference from neighbouring cells. This cell 
chip is an open system and very easy to use, so all of the procedures are performed 
only once, but not well by well if using multi-well plates. Cells on one chip are 
cultured and treated with the same condition, which results in low variation.  
 
We demonstrated this method for investigation of cell migration study. Furthermore, 
it will be readily adapted to perform large scale screens of functional genes regulating 
22 
 
other phenotypes, such as cell apoptosis, cell autophagy, sugar metabolism, and 
mitochondria morphology (Figure 2.4).  
 
 
Figure 2.4 Applications of SAMcell  
a. Annexin V/PI co-staining assay to detect cell apoptosis. Annexin V (green) 
indicated cells with apoptosis. PI (red) indicated cells with necrosis. 








CHAPTER 3                                      
SCREENING OF HUMAN GENOME MIRNAS REGULATING 
CANCER METASTASIS 
 
3.1 Screening of miRNAs regulating cell migration 
 
Thanks to the development of SAMcell chip, we set up a HTS system to investigate 
miRNAs involved in cancer metastasis. We took use of Hela cells (human cervix 
cancer cells) to perform the screens, because Hela is one of the most popular and 
stable cell lines. As shown in Figure 3.1a, the functional screen started with migration 
assays including SAMcell assay for primary screen and Transwell migration assay for 
validation, followed by gel-coated Transwell invasion assay and apoptosis assay. In 
total, over 900 miRNAs were investigated (Table 3.1A). The primary screen indicated 
that 201 miRNA genes are able to regulate cell migration. To assess the quality of our 
screening method, we validated the positive representative miRNAs (PR-miRNAs) 
through conventional Transwell migration assay. In total, 182 miRNA genes (20%) 
demonstrated consistent behaviour in both assays (Figure 3.1b and Table 3.1B). 
Analysis of the 19 miRNAs exhibiting non-concordant behaviour found that 18 of 
them exerted a potent effect on cell proliferation, that is, less than 2 % of the false 
positive results being due to the influence of proliferation in this assay (Table 3.1C).  
Additionally, we also randomly selected 10 miRNAs incapable of regulating cells 
migration (negative representative miRNAs, or NR-miRNAs) and individually 
examined the migratory regulation capability of each miRNA by means of the 
Transwell migration assay. Unsurprisingly, none of them exhibited any significant 





Figure 3.1 Screening of miRNAs regulating cancer cell migration 
a. Screening strategy used to perform the functional screen. 
b. Pie diagram showed the distribution of the migratory miRNAs. The 2% false 
positives are mainly due to proliferation. 
c. Ten NR miRNAs were confirmed to have no effect on the migration of Hela cells 
(black bar) by use of the Transwell migration assay. It was also observed that these 
miRNAs demonstrated the same incapacity to regulate the mobility of MCF-7 cells 
(white bar).  
 
Table 3.1A List of human miRNAs examined in this work 
miR-1 miR-570 miR-1259 miR-106b miR-28-5p miR-514b-3p 
miR-7 miR-571 miR-1260 miR-106b* miR-296-3p miR-514b-5p 
miR-9 miR-572 miR-1261 miR-10a miR-296-5p miR-515-3p 
miR-16 miR-573 miR-1262 miR-10b miR-299-3p miR-515-5p 
miR-17 miR-575 miR-1263 miR-10b* miR-299-5p miR-516a-3p 
miR-21 miR-577 miR-1264 miR-1207-3p miR-29a  miR-516a-5p 
miR-22 miR-578 miR-1265 miR-1207-5p miR-29a* miR-516b 
miR-24 miR-579 miR-1266 miR-122* miR-29b miR-516b* 
miR-25 miR-580 miR-1267 miR-1224-3p miR-29c miR-517* 
miR-31 miR-581 miR-1268 miR-1224-5p miR-301a miR-517a 
miR-32 miR-583 miR-1269 miR-1225-3p miR-301b miR-517b 
miR-93 miR-584 miR-1270 miR-1225-5p miR-302a miR-517c 
miR-95 miR-585 miR-1271 miR-1226* miR-302a* miR-518a-3p 
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Table 3.1A Continued 
miR-96 miR-586 miR-1272 miR-1228* miR-302b miR-518a-5p 
miR-98 miR-587 miR-1273 miR-124* miR-302b* miR-518b 
miR-100 miR-588 miR-1275 miR-1255a miR-302c miR-518c 
miR-101 miR-589 miR-1276 miR-1255b miR-302c* miR-518c* 
miR-103 miR-591 miR-1277 miR-125a-3p miR-302d miR-518d-3p 
miR-105 miR-592 miR-1278 miR-125a-5p miR-302d* miR-518d-5p 
miR-107 miR-593 miR-1279 miR-125b miR-302e miR-518e 
miR-122 miR-595 miR-1280 miR-126* miR-302f miR-518e* 
miR-124 miR-596 miR-1281 miR-127-3p miR-3065-3p miR-518f 
miR-126 miR-597 miR-1282 miR-1274a miR-3065-5p miR-518f* 
miR-128 miR-598 miR-1283 miR-1274b miR-30a miR-519a 
miR-132 miR-599 miR-1284 miR-127-5p miR-30b miR-519a* 
miR-134 miR-600 miR-1285 miR-129* miR-30b* miR-519b-3p 
miR-136 miR-601 miR-1286 miR-129-3p miR-30c miR-519b-5p 
miR-137 miR-602 miR-1287 miR-129-5p miR-30c-1* miR-519c-3p 
miR-138 miR-603 miR-1288 miR-130a miR-30c-2* miR-519c-5p 
miR-141 miR-604 miR-1289 miR-130a* miR-30d miR-519d 
miR-143 miR-605 miR-1290 miR-130b miR-30d* miR-519e 
miR-144 miR-606 miR-1291 miR-130b* miR-30e miR-519e* 
miR-145 miR-607 miR-1292 miR-132* miR-30e* miR-520a-3p 
miR-147 miR-608 miR-1293 miR-133a miR-31* miR-520a-5p 
miR-149 miR-609 miR-1294 miR-133b miR-3126-3p miR-520b 
miR-150 miR-610 miR-1295 miR-135a miR-3130-3p miR-520c-3p 
miR-152 miR-611 miR-1296 miR-135a* miR-3130-5p miR-520c-5p 
miR-153 miR-612 miR-1297 miR-135b miR-3144-3p miR-520d-3p 
miR-154 miR-613 miR-1298 miR-135b* miR-3144-5p miR-520d-5p 
miR-155 miR-614 miR-1299 miR-136* miR-3186-5p miR-520e 
miR-182 miR-616 miR-1301 miR-138-1* miR-3190-5p miR-520f 
miR-184 miR-617 miR-1302 miR-138-2* miR-320a miR-520g 
miR-185 miR-618 miR-1303 miR-139-3p miR-320b miR-520h 
miR-186 miR-619 miR-1304 miR-139-5p miR-320c miR-522* 
miR-187 miR-620 miR-1305 miR-140-3p miR-323-3p miR-523* 
miR-190 miR-621 miR-1306 miR-140-5p miR-323-5p miR-524-3p 
miR-191 miR-622 miR-1307 miR-141* miR-323b-5p miR-524-5p 
miR-192 miR-623 miR-1308 miR-142-3p miR-324-3p miR-525-3p 
miR-194 miR-624 miR-1321 miR-142-5p miR-324-5p miR-526a 
miR-195 miR-625 miR-1322 miR-143* miR-330-3p miR-526b 
miR-197 miR-626 miR-1323 miR-144* miR-330-5p miR-526b* 
miR-198 miR-627 miR-1324 miR-145* miR-331-3p miR-532-3p 
miR-202 miR-629 miR-1468 miR-146a miR-331-5p miR-532-5p 
miR-203 miR-632 miR-1469 miR-146a* miR-335* miR-541* 
miR-204 miR-634 miR-1470 miR-146b-3p miR-337-3p miR-542-3p 
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Table 3.1A Continued 
miR-206 miR-635 miR-1471 miR-146b-5p miR-337-5p miR-542-5p 
miR-210 miR-637 miR-1537 miR-148a miR-338-3p miR-544b 
miR-211 miR-639 miR-1538 miR-148a* miR-338-5p miR-545* 
miR-212 miR-640 miR-1539 miR-148b miR-339-3p miR-548a-3p 
miR-214 miR-643 miR-1825 miR-148b* miR-339-5p miR-548a-5p 
miR-215 miR-644 miR-1826 miR-149* miR-33a miR-548b-3p 
miR-217 miR-646 miR-1827 miR-150* miR-33a* miR-548b-5p 
miR-218 miR-647 miR-1908 miR-151-3p miR-33b miR-548c-3p 
miR-221 miR-649 miR-1909 miR-151-5p miR-340* miR-548c-5p 
miR-222 miR-650 miR-1910 miR-154* miR-342-3p miR-548d-3p 
miR-223 miR-655 miR-1911 miR-155* miR-342-5p miR-548d-5p 
miR-224 miR-656 miR-1912 miR-15a miR-34a miR-548e 
miR-297 miR-657 miR-1913 miR-15a* miR-34a* miR-548f 
miR-300 miR-658 miR-1915 miR-15b miR-34b miR-548g 
miR-325 miR-659 miR-1972 miR-15b* miR-34b* miR-548h 
miR-328 miR-661 miR-1973 miR-16-1* miR-34c-3p miR-548i 
miR-329 miR-663 miR-1975 miR-16-2* miR-34c-5p miR-548j 
miR-335 miR-664 miR-1976 miR-17* miR-361-3p miR-548k 
miR-340 miR-665 miR-1979 miR-181a miR-361-5p miR-548l 
miR-345 miR-668 miR-2052 miR-181a* miR-362-3p miR-548m 
miR-346 miR-670 miR-2053 miR-181a-2* miR-362-5p miR-548n 
miR-363 miR-675 miR-2054 miR-181b miR-363* miR-548o 
miR-365 miR-711 miR-2110 miR-181c miR-365* miR-548p 
miR-367 miR-718 miR-2113 miR-181d miR-367* miR-548q 
miR-370 miR-720 miR-2114 miR-182* miR-369-3p miR-548s 
miR-372 miR-758 miR-2115 miR-183* miR-369-5p miR-548t 
miR-373 miR-759 miR-2116 miR-186* miR-371-3p miR-548w 
miR-375 miR-761 miR-2117 miR-187* miR-371-5p miR-548x 
miR-377 miR-762 miR-2276 miR-188-3p miR-373* miR-550* 
miR-378 miR-764 miR-2277 miR-18a miR-374a miR-551a 
miR-379 miR-765 miR-2278 miR-18a* miR-374a* miR-551b 
miR-380 miR-766 miR-2909 miR-18b miR-374b miR-551b* 
miR-381 miR-802 miR-3119 miR-1909* miR-374b* miR-556-3p 
miR-382 miR-873 miR-3123 miR-190b miR-376a miR-556-5p 
miR-383 miR-874 miR-3124 miR-191* miR-376a* miR-574-3p 
miR-384 miR-887 miR-3127 miR-1915* miR-376b miR-574-5p 
miR-410 miR-888 miR-3128 miR-193a-3p miR-376c miR-576-3p 
miR-411 miR-889 miR-3131 miR-193a-5p miR-377* miR-576-5p 
miR-412 miR-890 miR-3132 miR-193b miR-378* miR-582-3p 
miR-421 miR-920 miR-3133 miR-195* miR-378b miR-582-5p 
miR-424 miR-921 miR-3134 miR-196a miR-379* miR-589* 
miR-425 miR-922 miR-3135 miR-196a* miR-380* miR-590-3p 
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Table 3.1A Continued 
miR-429 miR-924 miR-3136 miR-196b miR-409-3p miR-590-5p 
miR-431 miR-933 miR-3137 miR-196b* miR-409-5p miR-593* 
miR-432 miR-934 miR-3138 miR-199a-3p miR-422a miR-615-3p 
miR-433 miR-935 miR-3139 miR-199a-5p miR-423-3p miR-615-5p 
miR-448 miR-936 miR-3140 miR-199b-3p miR-423-5p miR-616* 
miR-451 miR-937 miR-3141 miR-199b-5p miR-424* miR-624* 
miR-452 miR-938 miR-3142 miR-19a miR-425* miR-625* 
miR-454 miR-939 miR-3143 miR-19a* miR-431* miR-628-3p 
miR-466 miR-940 miR-3145 miR-19b miR-432* miR-654-3p 
miR-484 miR-941 miR-3147 miR-200a miR-449a miR-654-5p 
miR-488 miR-942 miR-3149 miR-200b miR-449b miR-663b 
miR-489 miR-943 miR-3150 miR-200b* miR-449b* miR-664* 
miR-492 miR-944 miR-3151 miR-200c miR-449c miR-671-3p 
miR-493 miR-1178 miR-3152 miR-202* miR-449c* miR-671-5p 
miR-494 miR-1179 miR-3153 miR-205* miR-450a miR-675* 
miR-495 miR-1180 miR-3155 miR-208a miR-450b-3p miR-7-2* 
miR-496 miR-1181 miR-3156 miR-208b miR-450b-5p miR-767-3p 
miR-497 miR-1182 miR-3157 miR-20a miR-452* miR-767-5p 
miR-498 miR-1183 miR-3158 miR-20a* miR-454* miR-769-3p 
miR-500 miR-1184 miR-3159 miR-20b miR-455-3p miR-769-5p 
miR-503 miR-1185 miR-3160 miR-20b* miR-455-5p miR-770-5p 
miR-504 miR-1197 miR-3162 miR-2115* miR-483-3p miR-875-3p 
miR-505 miR-1200 miR-3163 miR-2116* miR-483-5p miR-875-5p 
miR-506 miR-1201 miR-3164 miR-216a miR-485-3p miR-876-3p 
miR-507 miR-1202 miR-3165 miR-216b miR-485-5p miR-876-5p 
miR-510 miR-1203 miR-3166 miR-218-1* miR-486-3p miR-877* 
miR-511 miR-1204 miR-3167 miR-218-2* miR-486-5p miR-885-3p 
miR-514 miR-1205 miR-3168 miR-219-1-3p miR-487a miR-885-5p 
miR-521 miR-1206 miR-3170 miR-219-2-3p miR-487b miR-886-3p 
miR-522 miR-1208 miR-3171 miR-219-5p miR-488* miR-886-5p 
miR-523 miR-1226 miR-3172 miR-22* miR-490-3p miR-891a 
miR-527 miR-1227 miR-3174 miR-220a miR-490-5p miR-891b 
miR-539 miR-1228 miR-3175 miR-220b miR-491-3p miR-892b 
miR-541 miR-1229 miR-3176 miR-220c miR-491-5p miR-9* 
miR-543 miR-1231 miR-3177 miR-221* miR-493* miR-92a 
miR-544 miR-1233 miR-3178 miR-222* miR-497* miR-92a-1* 
miR-545 miR-1234 miR-3181 miR-223* miR-499-3p miR-92a-2* 
miR-549 miR-1236 miR-3182 miR-224* miR-499-5p miR-92b 
miR-550 miR-1237 miR-3183 miR-23a miR-500* miR-93* 
miR-552 miR-1238 miR-3184 miR-23a* miR-501-3p miR-96* 
miR-553 miR-1243 miR-3187 miR-23b miR-501-5p miR-99a 
miR-554 miR-1244 miR-3188 miR-23b* miR-502-3p miR-99a* 
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Table 3.1A Continued 
miR-555 miR-1245 miR-3189 miR-24-1* miR-502-5p miR-99b 
miR-557 miR-1246 miR-3197 miR-24-2* miR-505* miR-99b* 
miR-558 miR-1247 miR-3198 miR-25* miR-508-3p let-7a 
miR-559 miR-1248 miR-3199 miR-26a  miR-508-5p let-7b 
miR-561 miR-1249 miR-3200 miR-26a-1* miR-509-3p let-7c 
miR-562 miR-1250 miR-100* miR-26a-2* miR-509-5p let-7d 
miR-563 miR-1251 miR-101* miR-26b miR-512-3p let-7e 
miR-564 miR-1252 miR-103-2* miR-27a miR-512-5p let-7f 
miR-566 miR-1253 miR-103-as miR-27a* miR-513a-3p let-7g 
miR-567 miR-1254 miR-105* miR-27b miR-513a-5p let-7i 
miR-568 miR-1256 miR-106a miR-27b* miR-513b  
miR-569 miR-1257 miR-106a* miR-28-3p miR-513c  
 
Table 3.1B List of miRNAs capable of regulating cell migration   
No. miRNA SAMcell chip Transwell 
1 miR-1287 Inhibit *** Inhibit ** 
2 miR-1306 Inhibit *** Inhibit ** 
3 miR-658 Inhibit *** Inhibit ** 
4 miR-1295 Inhibit *** Inhibit ** 
5 miR-185 Inhibit *** Inhibit *** 
6 miR-1255a Inhibit *** Inhibit ** 
7 miR-421 Inhibit ** Inhibit ** 
8 miR-32 Inhibit ** Inhibit ** 
9 miR-132 Inhibit ** Inhibit ** 
10 miR-let-7f Inhibit ** Inhibit * 
11 miR-95 Inhibit ** Inhibit ** 
12 miR-206 Inhibit ** Inhibit *** 
13 miR-593* Inhibit ** Inhibit *** 
14 miR-498 Inhibit ** Inhibit ** 
15 miR-596 Inhibit ** Inhibit ** 
16 miR-485-5p Inhibit ** Inhibit * 
17 miR-222 Inhibit ** Inhibit * 
18 miR-188-3p Inhibit ** Inhibit ** 
19 miR-302b Inhibit ** Inhibit ** 
20 miR-124 Inhibit ** Inhibit ** 
21 miR-143 Inhibit ** Inhibit *** 
22 miR-145 Inhibit ** Inhibit *** 
23 miR-497 Inhibit ** Inhibit ** 
24 miR-450b-5p Inhibit ** Inhibit ** 
25 miR-1469 Inhibit ** Inhibit ** 
26 miR-let-7e Inhibit ** Inhibit * 
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Table 3.1B Continued 
27 miR-1915* Inhibit ** Inhibit * 
28 miR-128 Inhibit * Inhibit * 
29 miR-192 Inhibit * Inhibit ** 
30 miR-215 Inhibit * Inhibit * 
31 miR-126* Inhibit * Inhibit * 
32 miR-33b Inhibit * Inhibit * 
33 miR-17 Inhibit * Inhibit * 
34 miR-25 Inhibit * Inhibit ** 
35 miR-451 Inhibit * Inhibit *** 
36 miR-663 Inhibit * Inhibit * 
37 miR-133a Inhibit * Inhibit * 
38 miR-23b Inhibit * Inhibit ** 
39 miR-29a* Inhibit * Inhibit * 
40 miR-320a Inhibit * Inhibit * 
41 miR-34b Inhibit * Inhibit * 
42 miR-767-3p Inhibit * Inhibit * 
43 miR-98 Inhibit * Inhibit * 
44 miR-555 Inhibit * Inhibit * 
45 miR-606 Inhibit * Inhibit * 
46 miR-611 Inhibit * Inhibit * 
47 miR-25* Inhibit * Inhibit * 
48 miR-204 Inhibit * Inhibit ** 
49 miR-221 Inhibit * Inhibit * 
50 miR-1183 Inhibit * Inhibit * 
51 miR-1266 Inhibit * Inhibit * 
52 miR-1324 Inhibit * Inhibit ** 
53 miR-512-3p Inhibit * Inhibit * 
54 miR-34c-5p Inhibit * Inhibit * 
55 miR-9 Inhibit * Inhibit * 
56 miR-101 Inhibit * Inhibit ** 
57 miR-559 Inhibit * Inhibit * 
58 miR-1975 Inhibit * Inhibit * 
59 miR-1207-5p Inhibit * Inhibit * 
60 miR-200c Inhibit * Inhibit ** 
61 miR-29b Inhibit * Inhibit * 
62 miR-34a Inhibit * Inhibit ** 
63 miR-671-5p Inhibit * Inhibit * 
64 miR-let-7b Inhibit * Inhibit * 
65 miR-548m Inhibit * Inhibit ** 
66 miR-190 Inhibit * Inhibit ** 
67 miR-31 Inhibit * Inhibit ** 
68 miR-661 Inhibit * Inhibit * 
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Table 3.1B Continued 
69 miR-125a-5p Inhibit * Inhibit * 
70 miR-200b Inhibit * Inhibit * 
71 miR-490-5p Inhibit * Inhibit * 
72 miR-517a Inhibit * Inhibit * 
73 miR-548d-3p Inhibit * Inhibit * 
74 miR-let-7a Inhibit * Inhibit ** 
75 miR-133b Inhibit * Inhibit ** 
76 miR-200a Inhibit * Inhibit ** 
77 miR-22 Inhibit * Inhibit ** 
78 miR-1201 Inhibit * Inhibit * 
79 miR-30c-1* Inhibit * Inhibit * 
80 miR-320c Inhibit * Inhibit * 
81 miR-548e Inhibit * Inhibit * 
82 miR-126 Inhibit * Inhibit ** 
83 miR-138 Inhibit * Inhibit ** 
84 miR-586 Inhibit * Inhibit * 
85 miR-1307 Inhibit * Inhibit * 
86 miR-29a  Inhibit * Inhibit ** 
87 miR-29c Inhibit * Inhibit ** 
88 miR-373* Inhibit * Inhibit ** 
89 miR-548h Inhibit * Inhibit * 
90 miR-1181 Inhibit * Inhibit * 
91 miR-320b Inhibit * Inhibit * 
92 miR-1 Inhibit * Inhibit * 
93 miR-7 Inhibit * Inhibit * 
94 miR-297 Inhibit * Inhibit ** 
95 miR-433 Inhibit * Inhibit * 
96 miR-492 Inhibit * Inhibit * 
97 miR-592 Inhibit * Inhibit * 
98 miR-18b Inhibit * Inhibit ** 
99 miR-208b Inhibit * Inhibit * 
100 miR-22* Inhibit * Inhibit ** 
101 miR-26a  Inhibit * Inhibit ** 
102 miR-552 Inhibit * Inhibit * 
103 miR-554 Inhibit * Inhibit ** 
104 miR-1262 Inhibit * Inhibit * 
105 miR-1979 Inhibit * Inhibit * 
106 miR-199b-5p Inhibit * Inhibit * 
107 miR-let-7g Inhibit * Inhibit * 
108 miR-937 Inhibit * Inhibit * 
109 miR-523* Inhibit * Inhibit * 
110 miR-20a* Inhibit * Inhibit * 
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Table 3.1B Continued 
111 miR-19b Promote * Promote ** 
112 miR-20a Promote * Promote * 
113 miR-518d-5p Promote * Promote * 
114 miR-516b* Promote * Promote ** 
115 miR-548g Promote * Promote * 
116 miR-367 Promote * Promote ** 
117 miR-575 Promote * Promote ** 
118 miR-612 Promote * Promote * 
119 miR-1283 Promote * Promote * 
120 miR-202* Promote * Promote ** 
121 miR-513a-3p Promote * Promote *** 
122 miR-548f Promote * Promote * 
123 miR-103 Promote * Promote * 
124 miR-106b Promote * Promote * 
125 miR-135b Promote * Promote * 
126 miR-30d Promote * Promote * 
127 miR-518f* Promote * Promote * 
128 miR-548k Promote * Promote ** 
129 miR-210 Promote * Promote * 
130 miR-218 Promote * Promote ** 
131 miR-219-5p Promote * Promote * 
132 miR-28-5p Promote * Promote * 
133 miR-296-3p Promote * Promote * 
134 miR-302d Promote * Promote * 
135 miR-574-5p Promote * Promote * 
136 miR-590-5p Promote * Promote * 
137 miR-107 Promote * Promote ** 
138 miR-539 Promote * Promote ** 
139 miR-550 Promote * Promote ** 
140 miR-1250 Promote * Promote ** 
141 miR-193a-3p Promote * Promote ** 
142 miR-335* Promote * Promote *** 
143 miR-483-5p Promote * Promote ** 
144 miR-1323 Promote * Promote * 
145 miR-181b Promote * Promote *** 
146 miR-511 Promote * Promote * 
147 miR-1227 Promote * Promote * 
148 miR-151-5p Promote * Promote * 
149 miR-520c-5p Promote * Promote ** 
150 miR-99a Promote * Promote * 
151 miR-373 Promote * Promote ** 
152 miR-501-3p Promote * Promote ** 
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Table 3.1B Continued 
153 miR-153 Promote ** Promote * 
154 miR-340 Promote ** Promote * 
155 miR-665 Promote ** Promote * 
156 miR-93 Promote ** Promote ** 
157 miR-155 Promote ** Promote ** 
158 miR-429 Promote ** Promote * 
159 miR-130b Promote ** Promote * 
160 miR-196a Promote ** Promote ** 
161 miR-27b Promote ** Promote ** 
162 miR-302b* Promote ** Promote * 
163 miR-30b Promote ** Promote * 
164 miR-211 Promote ** Promote * 
165 miR-494 Promote ** Promote ** 
166 miR-20b Promote ** Promote * 
167 miR-369-5p Promote ** Promote ** 
168 miR-522* Promote ** Promote *** 
169 miR-520c-3p Promote ** Promote ** 
170 miR-99b Promote ** Promote ** 
171 miR-154 Promote ** Promote ** 
172 miR-1913 Promote ** Promote * 
173 miR-593 Promote ** Promote * 
174 miR-367* Promote ** Promote ** 
175 miR-339-5p Promote ** Promote * 
176 miR-632 Promote ** Promote *** 
177 miR-214 Promote *** Promote *** 
178 miR-510 Promote *** Promote ** 
179 miR-639 Promote *** Promote *** 
180 miR-10a Promote *** Promote ** 
181 miR-21 Promote *** Promote *** 
182 miR-10b Promote *** Promote *** 
 
Note:  SAMcell chip,  * 10%-20%;  ** 20%-30%; *** >30%.   Transwell,  * 
15%-30%; ** 30%-60%; *** >60%. 
 
Table 3.1C List of miRNAs demonstrating non-concordant behaviors 
No. miRNA SAMcell chip Transwell Proliferation 
1 miR-345 Inhibit * - - 
2 miR-222* Inhibit * - Inhibit * 
3 miR-217 Inhibit * - Inhibit * 
4 miR-579 Inhibit * - Inhibit * 
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Table 3.1C Continued 
5 miR-335 Inhibit * - Inhibit * 
6 miR-583 Inhibit * Promote * Inhibit * 
7 miR-518a-5p Inhibit * - Inhibit * 
8 miR-302c* Inhibit * - Inhibit * 
9 miR-524-5p Inhibit * - Inhibit * 
10 miR-let-7c Inhibit * - Inhibit * 
11 miR-376c Inhibit * Promote * Inhibit * 
12 miR-28-3p Promote * Inhibit * Promote * 
13 miR-520e Promote * - Promote * 
14 miR-20b* Promote * Inhibit * Promote * 
15 miR-26b Promote * Inhibit * Promote * 
16 miR-194 Promote * - Promote ** 
17 miR-134 Promote * - Promote * 
18 miR-220a Promote ** Inhibit * Promote ** 
19 miR-591 Promote ** Inhibit * Promote ** 
Note:  SAMcell chip,  * 10%-20%;  ** 20%-30%; *** >30%.   Transwell,  * 
15%-30%; ** 30%-60%; *** >60%.  Proliferation,  *10%-20%; ** >20%. 
 
3.2 General regulation of miRNA on cell migration 
 
To investigate whether the screening results, including both the negative and positive 
ones, are applicable to other cells in addition to Hela cells, we first delivered the 
above-mentioned NR-miRNAs into MCF-7 cells, which are human breast cancer cells. 
Unsurprisingly, these miRNAs consistently demonstrated an inability to regulate the 
mobility of MCF-7 (Figure 3.1c). We then randomly selected 20 miRNAs from the 
screening list as positive representative miRNAs (PR-miRNAs), and examined their 
migratory regulation capacity in three other epithelial cancer cell lines, MCF-7 
(human breast cancer cell), Panc-1 (human pancreas cancer cell) and HCT 116 
(human colon cancer cell). It was observed that almost all of them exhibited the same 
regulatory capacity in these three cell lines as in Hela cell line, with the exception of a 
few miRNAs which did not have any evident impact (Figure 3.2a). Taken together, 
these results imply that the screening results based on Hela cells may be applicable to 
other epithelial cancer cell lines, and thus are of potentially general use. These 
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migratory miRNAs exhibit versatility in diverse cell types, including four types of 
epithelial cells as well as HUVEC cells (Figure 3.2b), which are human umbilical vein 
endothelial cells, thus being of general functionality. Given the fact that cell migration 
is a basic biological process, we hypothesize that a general regulation of migratory 
behaviour seems to be another distinctive feature of miRNAs. 
 
Figure 3.2 General regulation of miRNA on cell migration 
a. General regulation of miRNA on the migratory behaviours. Noticeably, no 
miRNAs exhibited a contrasting migratory regulation capacity. Transwell cell 
migration assay was used here. Red, green or black means up-regulated activity, 
down-regulated activity, or no significant change, respectively. 
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b. Migration assays of Hela (blue bar) and HUVEC cells (red bar) transfected with 
indicated miRNAs. Noticeably, no miRNAs exhibited a contrasting migratory 
regulation capacity.  
 
 
3.3 Results of the miRNA functional screens 
 
Next, we concentrated on the migration-suppressing miRNAs and investigated their 
capacity to regulate cell invasion or apoptosis, since most miRNAs are pathologically 
down-expressed in cancer samples. The results showed that 69 of these miRNAs 
significantly suppressed invasion in vitro (Table 3.3A), among which 36 miRNAs 
were demonstrated to be capable of inducing apoptosis (Figure 3.3 and Table 3.3B). 
Importantly, dozens of well characterized miRNAs, including miR-101, the miR-200 
family and let-7a/b are included in our screening results. Each of the miRNAs was 
ranked by the capacity to regulate migration, invasion and apoptosis activity. Our data 
show that miR-23b is capable of not only inhibiting both migration and invasion, but 
also inducing apoptosis effectively. According to the formula defined in Table 3.3B, 





Figure 3.3 Results of the miRNA functional screens.  
miRNAs previously reported to regulate cell migration, invasion or apoptosis are 
highlighted in blue. miR-23b in red is the final gene with the highest scores.  
 
Table 3.3A List of miRNAs capable of inhibiting cell invasion 
No. miRNA Migration Invasion 
1 miR-1 Inhibit * - 
2 miR-7 Inhibit * Inhibit * 
3 miR-9 Inhibit * - 
4 miR-17 Inhibit * Inhibit ** 
5 miR-22 Inhibit ** Inhibit * 
6 miR-25 Inhibit ** Inhibit ** 
7 miR-31 Inhibit ** Inhibit ** 
8 miR-32 Inhibit ** Inhibit *** 
9 miR-95 Inhibit ** - 
10 miR-98 Inhibit * Inhibit * 
11 miR-101 Inhibit ** Inhibit * 
12 miR-124 Inhibit ** Inhibit ** 
13 miR-126 Inhibit ** Inhibit * 
14 miR-128 Inhibit * Inhibit *** 
15 miR-132 Inhibit ** - 
16 miR-138 Inhibit ** Inhibit *** 
17 miR-143 Inhibit *** Inhibit ** 
18 miR-145 Inhibit *** Inhibit ** 
19 miR-185 Inhibit *** Inhibit *** 
20 miR-190 Inhibit ** Inhibit ** 
21 miR-192 Inhibit ** Inhibit * 
22 miR-204 Inhibit ** - 
23 miR-206 Inhibit *** Inhibit ** 
24 miR-215 Inhibit * Inhibit ** 
25 miR-221 Inhibit * - 
26 miR-222 Inhibit * - 
27 miR-297 Inhibit ** - 
28 miR-421 Inhibit ** Inhibit ** 
29 miR-433 Inhibit * Inhibit * 
30 miR-451 Inhibit *** Inhibit *** 
31 miR-492 Inhibit * Inhibit * 
32 miR-497 Inhibit ** Inhibit ** 
33 miR-498 Inhibit ** Inhibit ** 
34 miR-552 Inhibit * Inhibit *** 
35 miR-554 Inhibit ** - 
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Table 3.3A Continued 
36 miR-555 Inhibit * - 
37 miR-559 Inhibit * Inhibit * 
38 miR-586 Inhibit * - 
39 miR-592 Inhibit * - 
40 miR-596 Inhibit ** Inhibit ** 
41 miR-606 Inhibit * - 
42 miR-611 Inhibit * Inhibit ** 
43 miR-658 Inhibit ** - 
44 miR-661 Inhibit * - 
45 miR-663 Inhibit * - 
46 miR-937 Inhibit * Inhibit ** 
47 miR-1181 Inhibit * Inhibit *** 
48 miR-1183 Inhibit * - 
49 miR-1201 Inhibit * Inhibit ** 
50 miR-1262 Inhibit * - 
51 miR-1266 Inhibit * Inhibit *** 
52 miR-1287 Inhibit ** - 
53 miR-1295 Inhibit ** - 
54 miR-1306 Inhibit ** Inhibit *** 
55 miR-1307 Inhibit * Inhibit *** 
56 miR-1324 Inhibit ** - 
57 miR-1469 Inhibit ** Inhibit *** 
58 miR-1975 Inhibit * Inhibit *** 
59 miR-1979 Inhibit * Inhibit *** 
60 miR-1207-5p Inhibit * Inhibit *** 
61 miR-1255a Inhibit ** Inhibit *** 
62 miR-125a-5p Inhibit * Inhibit ** 
63 miR-126* Inhibit * - 
64 miR-133a Inhibit * - 
65 miR-133b Inhibit ** - 
66 miR-188-3p Inhibit ** Inhibit ** 
67 miR-18b Inhibit ** - 
68 miR-1915* Inhibit * - 
69 miR-199b-5p Inhibit * - 
70 miR-200a Inhibit ** Inhibit ** 
71 miR-200b Inhibit * Inhibit ** 
72 miR-200c Inhibit ** Inhibit ** 
73 miR-208b Inhibit * Inhibit ** 
74 miR-20a* Inhibit * - 
75 miR-22* Inhibit ** Inhibit ** 
76 miR-23b Inhibit ** Inhibit *** 
77 miR-25* Inhibit * Inhibit ** 
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Table 3.3A Continued 
78 miR-26a  Inhibit ** Inhibit * 
79 miR-29a  Inhibit ** Inhibit * 
80 miR-29a* Inhibit * Inhibit * 
81 miR-29b Inhibit * - 
82 miR-29c Inhibit ** Inhibit ** 
83 miR-302b Inhibit ** - 
84 miR-30c-1* Inhibit * - 
85 miR-320a Inhibit * - 
86 miR-320b Inhibit * - 
87 miR-320c Inhibit * - 
88 miR-33b Inhibit * Inhibit ** 
89 miR-34a Inhibit ** Inhibit * 
90 miR-34b Inhibit * Inhibit * 
91 miR-34c-5p Inhibit * Inhibit * 
92 miR-373* Inhibit ** Inhibit * 
93 miR-450b-5p Inhibit ** - 
94 miR-485-5p Inhibit * Inhibit ** 
95 miR-490-5p Inhibit * Inhibit ** 
96 miR-512-3p Inhibit * Inhibit * 
97 miR-517a Inhibit * - 
98 miR-523* Inhibit * - 
99 miR-548d-3p Inhibit * Inhibit * 
100 miR-548e Inhibit * Inhibit * 
101 miR-548h Inhibit * Inhibit * 
102 miR-548m Inhibit ** Inhibit *** 
103 miR-593* Inhibit *** Inhibit *** 
104 miR-671-5p Inhibit * - 
105 miR-767-3p Inhibit * - 
106 miR-let-7a Inhibit ** Inhibit ** 
107 miR-let-7b Inhibit * Inhibit ** 
108 miR-let-7e Inhibit * Inhibit ** 
109 miR-let-7f Inhibit * - 
110 miR-let-7g Inhibit * - 
Note:  Migration & Invasion,  - no significance; * 15%-30%; ** 30%-60%; 
*** >60%.   
 
Table 3.3B List of miRNAs capable of inhibiting cell migration, invasion and 
promoting apoptosis 
No. miRNA Migration Invasion Apoptosis Total scores 
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Table 3.3B Continued 
1 miR-22 Inhibit ** Inhibit * Promote ** 5* 
2 miR-101 Inhibit ** Inhibit * Promote ** 5* 
3 miR-128 Inhibit * Inhibit *** Promote ** 6* 
4 miR-138 Inhibit ** Inhibit *** Promote * 6* 
5 miR-143 Inhibit *** Inhibit ** Promote ** 7* 
6 miR-145 Inhibit *** Inhibit ** Promote ** 7* 
7 miR-185 Inhibit *** Inhibit *** Promote * 7* 
8 miR-190 Inhibit ** Inhibit ** Promote * 5* 
9 miR-206 Inhibit *** Inhibit ** Promote * 6* 
10 miR-421 Inhibit ** Inhibit ** Promote * 5* 
11 miR-433 Inhibit * Inhibit * Promote * 3* 
12 miR-451 Inhibit *** Inhibit *** Promote * 7* 
13 miR-497 Inhibit ** Inhibit ** Promote * 5* 
14 miR-559 Inhibit * Inhibit * Promote * 3* 
15 miR-1181 Inhibit * Inhibit *** Promote * 5* 
16 miR-1201 Inhibit * Inhibit ** Promote * 4* 
17 miR-1266 Inhibit * Inhibit *** Promote * 5* 
18 miR-1469 Inhibit ** Inhibit *** Promote * 6* 
19 miR-1979 Inhibit * Inhibit *** Promote * 5* 
20 miR-1255a Inhibit ** Inhibit *** Promote * 6* 
21 miR-200a Inhibit ** Inhibit ** Promote * 5* 
22 miR-200b Inhibit * Inhibit ** Promote * 4* 
23 miR-200c Inhibit ** Inhibit ** Promote * 5* 
24 miR-22* Inhibit ** Inhibit ** Promote * 5* 
25 miR-23b Inhibit ** Inhibit *** Promote *** 8* 
26 miR-26a Inhibit ** Inhibit * Promote *** 6* 
27 miR-29a Inhibit ** Inhibit * Promote ** 5* 
28 miR-29a* Inhibit * Inhibit * Promote * 3* 
29 miR-29c Inhibit ** Inhibit ** Promote ** 6* 
30 miR-33b Inhibit * Inhibit ** Promote * 4* 
31 miR-34a Inhibit ** Inhibit * Promote ** 5* 
32 miR-34b Inhibit * Inhibit * Promote * 3* 
33 miR-34c-5p Inhibit * Inhibit * Promote ** 4* 
34 miR-593* Inhibit *** Inhibit *** Promote * 7* 
35 miR-let-7a Inhibit ** Inhibit ** Promote ** 6* 
36 miR-let-7b Inhibit * Inhibit ** Promote ** 5* 
Note:  Migration & Invasion, - no significance; * 15%-30%; ** 30%-60%; 
*** >60%.  Apoptosis,  * 25%-50%; ** 50%-100%; *** >100%. All data presented 
here stands for the decrement or increment compared to NC experimental data 
(scrambled siRNA): first normalized to NC data, and subtracted to 100 %. Total 
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score= Star No. of migration + Star No. of invasion + Star of apoptosis. miR-23b 
highlighted in red is the molecule with the highest score. 
 
3.4 miR-23b inhibiting metastasis-related traits 
 
Since miR-23b was the most powerful molecule to inhibiting cell motility and 
apoptosis in our screening results, we then deeply investigated its impact on many 
metastasis-related traits. An antagomir is a small synthetic RNA that is perfectly 
complementary to the specific miRNA target with either mispairing at the cleavage 
site of Ago2 or some sort of base modification to inhibit Ago2 cleavage[105]. We 
took use of miR-23b’s antagomir to silence endogenous miRNA. Ectopic expression 
of miR-23b produced a potent inhibition of the cell migration and invasion, but its 
antagomir increased the migratory and invasive activities by more than 40 % (Figure 
3.4a). Next, we also investigated the capability of cell proliferation regulated by 
miR-23b and its antagomir. We found that miR-23b resulted in a lower cell number 
over time but its antagomir distinctly increased the proliferation activity after 48 hours 
(Figure 3.4b and c). Furthermore, we took use of Annexin V/PI co-staining assay to 
detect whether miR-23b regulated cell apoptosis. Obviously, over-expression of 
miR-23b induced increasing ratio of cells with apoptosis and necrosis (Figure 3.4d). 
Anoikis is a form of programmed cell death which is induced by anchorage-dependent 
cells detaching from the surrounding extracellular matrix[106]. Our results showed 
that miR-23b resulted in higher ratio of anoikis-mediated cell death by more than 40% 





Figure 3.4 miR-23b inhibiting metastasis-related traits  
a. Migration (black bar) or invasion (grey bar) assay after transfection with the 
indicated RNAs in HCT 116 cells. n = 3.  
b. Proliferation assay after transfection with the indicated RNAs in HCT 116 cells at 
48 hours. n=3. 
c. Proliferation assay after transfection with the indicated RNAs in HCT 116 cells at 
different time points. n=3. 
d. Apoptosis assay after transfection with the indicated RNAs in HCT 116 cells after 
48 hours (quantified left). Annexin V (green) indicated cells with apoptosis. PI (red) 
indicated cells with necrosis. n=3. Scale bar: 50 μm. 
e. Anoikis assay after transfection with the indicated RNAs in HCT 116 cells after 48 
hours. n=3.  
 




Since epithelial to mesenchymal transition (EMT) is viewed as an essential early step 
in cancer metastasis, we examined whether miR-23b might regulate EMT through 
immunofluorescene assay. Immunofluorescene visualisation showed that miR-23b 
expression up-regulated E-cadherin (marker of epithelial stage) and down-regulated 
Vimentin (marker of mesenchymal stage), suggesting that the miR-23b may repress 
EMT process in cells (Figure 3.5a). We also took use of western blot assays to 
confirm this discovery. Obviously, over-expression of miR-23b resulted in higher 
E-cadherin level by 100% and lower Vimentin level by 60% (Figure 3.5b). These 
findings suggested that miR-23b might work at the early stage of cancer metastasis.  
 
 
Figure 3.5 miR-23b repressing EMT  
a. Manipulation of the miR-23b levels repressed the EMT. E-cadherin and Vimentin 
were detected by antibodies (green). Nuclei were detected by DAPI (blue). Scale bar: 
50 μm. 
b. Western blot assays showed the expression levels of E-cadherin and Vimentin in 




3.6 Expression patterns of miR-23b 
 
miR-23b is expressed in diverse colon cell lines. To determine whether the expression 
levels of miR-23b affect metastasis-relevant activities in human colon cancer, we 
selected seven human colon cancer cell lines, including HT29, LOVO, SW480, 
HCT116, HCT8, LS174T and SW620. HCT 116 has a lower expression level of 
miR-23b than HT29, LOVO or SW480, but a higher expression level than HCT29, 
LS174T or SW620 (Figure 3.6a). These cell lines demonstrated the reverse capability 
of migration and invasion to miR-23b levels (Figure 3.6b).  
 
To statistically investigate the expression profile of miR-23b, we collected more than 
100 of human colorectal tumor and normal adjunct tissue samples. Through a 
real-time detection method[107], expression analysis of miR-23b in these samples 
showed a higher mean expression in the normal samples (P < 3.0 X 10
-4
) (Figure 
3.6c). Furthermore, we divided the tumor samples into two groups according to 
whether they are obtained from metastasis-free or metastasis-positive patients, where 
metastasis positive means metastasic tumor has been identified, metastasis free means 
none metastasic tumor has been identified in surrounding ECM. We found that the 
mean expression level of miR-23b was 2-fold lower in the metastatic-free samples 
than the normal samples (P13 < 2.0 X 10
-6
) (Figure 3.6d). Unexpectedly, the mean 
expression of miR-23b was higher in the metastasis-positive samples compared to the 
metastasis-free samples (P23 < 0.01), although it was still lower compared to the levels 
in the normal samples (P12 < 0.05). Mann-Whitney U-test was used for calculating 
P-values, when two groups were compared. The P-value of the metastasis-free 
samples relative to the normal samples was much lower than the metastatic samples 
relative to either the normal or metastasis-free ones (that is, P13 << P12 or P23) (Figure 
3.6d), thus indicating a significant association between the expression level of 





Figure 3.6 miR-23b levels in human colon cancer cells and samples  
a. miR-23b levels in human colon cancer cell lines. U6 was used as an internal 
quantification control. n=3.  
b. The migration (black bar) or invasion (grey bar) activities of human colon cancer 
cell lines. n=5.  
c. Real-time PCR results for miR-23b in 104 human colon tumors or normal adjunct 
samples. There was a significant difference in miR-23b expression between these two 
groups (P < 3.0 X 10-4) (Mann-Whitney U-test). n=3.  
d. The same samples as in panel c were divided into three groups: normal adjunct 
samples, metastasis-positive cancer sample, and metastasis-free samples. There was a 
significant difference in miR-23b expression between these three groups (P13 < 
2X10
-6
, P23 < 0.05, P12 < 0.01) (Mann-Whitney U-test). n=3. 
 
3.7 miR-23b regulating a cohort of prometastatic genes 
 
To unveil the molecular mechanism of miR-23b, we employed three algorithms that 
predict the targets of miRNA, such as PicTar[108], TargetScan [109] and miRDB 
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[110]. More than 100 genes may be regulated by miR-23b on the basis of an 
agreement between at least two algorithms. We cloned the 3’ UTR of 28 putative 
miR-23b targets into a luciferase construct and performed quantitative examination of 
the luciferase activities. Reporter assays with miR-23b expressing HCT 116 cells 
revealed that a dozen putative targets were silenced by 35-75 % (Figure 3.7a). 
Mutation of the putative miR-23b site(s) in the 3’ UTR of FZD7, MAP3K1 
(MEKK1), PAK2, TGFβR2, RRAS2 or uPA resulted in an abrogated responsiveness 
to miR-23b (Figure 3.7b). The mutation of the miR-23b site(s) leads to almost 
identical activity to the wild-type reporters, suggesting the putative site(s) in the UTR 
of those genes is the main site targeted by miR-23b. Furthermore, the protein levels of 
these six genes were assayed in HCT 116 cells. Over-expression of miR-23b reduced 
the levels of these proteins by 35-70 % (Figure 3.7c).  
 
By now, we concluded the signaling pathways mediated by miR-23b in cancer cells 
(Figure 3.7d). miR-23b directly targets MAP3K1, RRAS2, PAK2, TGFBR2 and 
FZD7, resulting in negative regulation of NFKB, JNK, ERK, PI3K and ROCK1 
pathways. Consequently, cancer cell migration, invasion, and proliferation are 






Figure 3.7 miR-23b regulating a cohort of prometastatic genes  
a. Luciferase activity in HCT 116 cells infected with miR-23b (white bar) or control 
vector (black bar) after transfection with the indicated 3’ UTR-driven reporter 
constructs. n = 3. 
b. Luciferase activity in HCT 116 cells infected with miR-23b or control vector after 
transfection with the indicated 3’ UTR-driven reporter constructs. Black bar: 3’UTR + 
miR-23b; grey bar: mutation 3’UTR + miR-23b; white bar: 3’UTR + NC. n = 3. 
c. Immunoblots results for FZD7, MAP3K1, PAK2, RRAS2, TGFBR2 and UPA in 
the indicated HCT 116 cells. GAPDH was use as the loading control. Repression: 
protein levels in miR-23b-expressing cells relative to controls were repressed. 
d. Model of miR-23b mediated pathways in tumor growth and cancer metastasis. The 
key proteins directly targeted by miR-23b were highlighted in the pathways of NFKB, 
JNK, ERK, PI3K, ROCK1 and Wnt. 
 
3.8 Summary of miRNA screening 
 
More and more evidence has accumulated showing that miRNAs participate in 
cancerogenesis. It has thus become an essential task to identify physiologically 
relevant and therapeutically promising miRNAs[73, 111]. In this study, we 
systematically investigated the capacity of individual miRNAs in cancer cell 
migration, invasion and apoptosis. Through quantitatively examining the impact of all 
known human miRNAs on cell migration, we found that over 20 % miRNAs 
demonstrated a capacity to regulate cell mobility. What is also noted, these migratory 
miRNAs exhibited versatility in diverse cell types, including four types of epithelial 
cells as well as HUVECs, thus being of general functionality. Given the fact that cell 
migration is a basic biological process, we hypothesize that a general regulation of 




According to the best of our knowledge, approximately twenty miRNAs have been 
described as functionally regulating cell migration or metastasis in previous studies 
[64, 73]; almost all of which are included in our screening list, and these miRNAs 
exhibited exactly the same prometastic or antimetastatic activities in our screening 
assay as reported previously. For example, miR-10b or miR-21 promotes cell 
migration, while miR-31 or miR-101 has a suppressive impact[62, 73, 112, 113]. 
Further implementation of invasion or apoptosis assays resulted in the identification 
of 36 miRNAs capable of suppressing cancer cell migration, invasion and growth, 
among which more than half of them have not been characterized yet. These results 
suggest that more miRNAs might be identified which have potential as therapeutic 
reagents against cancer metastasis and development. 
 
miR-23b is highly conserved in all vertebrates. The data reported here demonstrated 
that miR-23b, which is down-regulated in human colon cancer samples, can potently 
repress cancer cell migration, invasion, growth and survival. It directly regulates a 
cohort of prometastatic genes or oncogenes, including FZD7, MAP3K1, PAK2, 
TGFβR2, RRAS2 and UPA. These six genes participate in certain critical signalling 
pathways, including the ERK, JNK, NFKB, PI3K, TGFB and Wnt pathways. To the 
best of our best knowledge, this is the first demonstration that so many critical 
pathways are interconnected in the regulation of metastasis under the control of a 
single miRNA-miR-23b.  
 
Collectively, the findings of the present study have important implications for the 
understanding of the universal dysregulation of miRNAs in human cancer progression, 
especially metastasis. We believe that these findings provide new insight into the 




CHAPTER 4                                      
SCREENING OF HUMAN GENOME KINASE GENES 
REGULATING CANCER METASTASIS 
 
4.1 Strategy of systematic investigation 
 
The strategy of investigation was schematically shown in Figure 4.1. At first, we used 
a RNAi-based on-chip assay, SAMcell[114], to systematically investigate 710 human 
kinase genes involved in cell migration. Then we validated the primary results by 
Transwell migration assay. Next, we further screened the invasion activity using the 
gel-coated Transwell invasion assay. Hela epithelial carcinoma cells were used in 
such functional screenings.  
 
Bio-informatics analysis started with differential expression strategy based on 
microarray dataset GSE6791[115] from cervix samples. Then gene ontology analysis 
was implemented by AmiGO[116] and KEGG[117]. Next, prePPI database[118] was 
used to predict protein-protein interactions. We identified sixteen important genes, 
including ten well-characterized genes and six prospective metastasis-related genes. 
Finally, all six prospective genes were examined by proliferation assay, apoptosis 





Figure 4.1 Strategy of functional screening and bio-informatics analysis. 
 
4.2 Loss-of-function study of kinase genes regulating cell migration 
 
We firstly used the SAMcell assay for high-throughput screening based on the cell 
migration performance. The assay conditions were established using siRNAs targeting 
AKT1, ROCK1 and ERBB2, which are famous metastasis-related kinase genes. The 
quantitative real-time RT–PCR results validated the silencing efficiency of these 
siRNAs (Figure 4.2a). As expected, the assay showed that cells moved faster when 
AKT1 was silenced, whereas cells migrated more slowly when either ROCK1 or 
ERBB2 was inhibited[95, 119, 120] (Figure 4.2b). By far, we set up a high-throughput 
system based on SAMcell assay and RNAi technology applying to loss-of-function 





Figure 4.2 Development of high-throughput system for screening cell migration. 
a. real-time PCR results indicated these genes can be efficiently silenced by the 
corresponding siRNAs in Hela. GAPDH was used as an internal quantification control. 
n=3.  
b. Representative Hela cell island images showed migration phenotypes. Scale bar: 
500um. Statistical results are shown in histogram on the right. n=4.  
c. Flow chart showed the pipelining of loss-of-function screening system.  
 
4.3 Functional screening for cell migration and invasion 
 
We performed the primary screening with SAMcell assay for cell migratory activities. 
In total, 710 kinase or kinase-like genes were investigated (Table 4.3A). The 
empirical fold-change cut-off was selected based on the fold-change distribution. That 
is, the significant genes should have the fold-change of migration less than 0.9 or 
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more than 1.1. With adjusted p-value threshold of 0.05, 86 genes were found to be PR 
genes (positive-representative genes) (Figure 4.3a).  
 
Next, we took use of Transwell assay, the most commonly used method for cell 
migration study, to validate the primary screening results. Among the 86 PR genes, 81 
demonstrated consistent behavior in both assays (Table 4.3B). Analysis of the other 5 
showing non-concordant behavior found that all of them exerted a potent effect on 
cell proliferation or apoptosis (Table 4.3C). Hence, 11% of kinase genes are able to 
regulate cancer cell migration (Figure 4.3b). Additionally, we randomly selected 15 
NR genes (negative representative genes) and examined their migration activities by 
Transwell assay. Unsurprisingly, none of them exhibited any significant change 
(Figure 4.3c). In total, there were 101 genes detected by both assays. By comparing 
the fold changes and sample deviations between the two assays, we observed that 
Transwell assay had wider fold-change range but higher variance, while SAMcell 
assay had smaller fold-change range but higher repeatability (Figure 4.3e). These 
findings suggest that SAMcell assay has higher stability than Transwell assay in cell 
migration study. 
 
The second round of functional screening was to detect the invasion activities. We 
screened the 81 migration-significant genes by gel-coated Transwell invasion assay. 
The significant genes had the fold-change of migration less than 0.8 or more than 1.2. 
With adjusted p-value threshold of 0.05, 47 genes were found to be significant genes 
regulating cell invasion (Figure 4.3d & Table 4.3D). Considering that migration and 
invasion are initial steps in the invasion-metastasis cascade, we hypothesized that 





Figure 4.3 Functional screening for kinase genes regulating migration and invasion. 
a. Volcano plot for distribution of 710 kinase siRNAs by primary screen. 4 replicate 
for each siRNA. Fold change is normalized to negative control (Scrambled siRNAs). 
The positive ones are marked in red, fold change >1.1 or <0.9 & adjusted P value 
<0.05 (log10).  
b. Pie diagram for the distribution of the migratory kinase genes. Hela was used in the 
primary screen and validation. The interference is due to proliferation and apoptosis 
effects. 
c. Fifteen NR genes were confirmed to have no effect on the migration in Hela cells. 
n=5.  
d. Heat map showed Migration/Invasion activities of 81 migration-significant genes 
treated with siRNAs in Hela via Transwell assay. Red, blue or black means 
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up-regulated activity, down-regulated activity, or no significant change, respectively. 
n=5. 
e. Distribution of fold change (left panel) or sample deviation (right panel) detected 
by both SAMcell and Transwell migration assays. The data points were ordered by 
red ones, data from Transwell assay. 
 
  
Table 4.3A List of entire 710 kinase genes screened 
AAK1 CDK6 ETNK2 LY6G5B NME1 PLXND1 STAP1 
AATK CDK7 FASTK LYN NME2 PMVK STAP2 
ABL1 CDK8 FER MADD NME3 PNCK STK10 
ABL2 CDK9 FES MAGI1 NME4 PNKP STK11 
ACVR1 CDKL1 FGFR1 MAGI2 NME5 PRKAA1 STK11IP 
ACVR1B CDKL2 FGFR2 MAGI3 NME6 PRKAA2 STK16 
ACVR1C CDKL3 FGFR3 MAK NME7 PRKACA STK17A 
ACVR2A CDKL4 FGFR4 MAP2K1 NRBP1 PRKACB STK17B 
ACVR2B CDKL5 FGFRL1 MAP2K1IP1 NRBP2 PRKACG STK19 
ACVRL1 CERK FGGY MAP2K2 NRGN PRKCA STK24 
ADCK2 CERKL FGR MAP2K3 NRK PRKCB1 STK25 
ADCK4 CHEK1 FLJ25006 MAP2K4 NTRK1 PRKCD STK3 
ADCK5 CHEK2 FLT1 MAP2K5 NTRK2 PRKCDBP STK32A 
ADK CHKA FLT3 MAP2K6 NTRK3 PRKCE STK32B 
ADPGK CHUK FLT4 MAP2K7 NUAK1 PRKCG STK32C 
ADRBK1 CIB1 FN3K MAP3K1 NUAK2 PRKCH STK33 
ADRBK2 CIB4 FN3KRP MAP3K10 OXSR1 PRKCI STK35 
AGK CIT FRAP1 MAP3K11 PACSIN1 PRKCQ STK36 
AK1 CKB FRK MAP3K12 PACSIN2 PRKCSH STK38 
AK2 CKM FUK MAP3K13 PACSIN3 PRKCZ STK38L 
AK3 CKMT1B FYN MAP3K14 PAK1 PRKD1 STK39 
AK3L1 CKMT2 GAK MAP3K15 PAK2 PRKD2 STK4 
AK3L2 CLK1 GALK1 MAP3K2 PAK3 PRKD3 STK40 
AK5 CLK2 GALK2 MAP3K3 PAK4 PRKDC STRADA 
AK7 CLK3 GCK MAP3K4 PAK6 PRKG1 STRADB 
AKAP12 CLK4 GCKR MAP3K5 PAK7 PRKG2 STYK1 
AKAP14 CMPK1 GK MAP3K6 PANK1 PRKX SYK 
AKAP7 CNKSR1 GK2 MAP3K7 PANK2 PRKY TAF1 
AKAP8 CNKSR3 GK5 MAP3K7IP2 PANK3 PRPF4B TAF1L 
AKAP8L COASY GLYCTK MAP3K8 PANK4 PRPS1 TAOK1 
AKT1 COL4A3BP GNE MAP3K9 PAPSS1 PRPS1L1 TAOK2 
AKT2 CRIM1 GRIP2 MAP4K1 PAPSS2 PRPS2 TAOK3 
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Table 4.3A Continued 
AKT3 CRKRS GRK1 MAP4K2 PASK PRPSAP1 TBK1 
ALDH18A1 CSF1R GRK4 MAP4K3 PBK PRPSAP2 tcag7.875 
ALK CSK GRK5 MAP4K4 PCM1 PSKH1 TEC 
ALPK1 CSNK1A1 GRK6 MAP4K5 PCTK1 PSKH2 TEK 
ALPK2 CSNK1A1L GRK7 MAPK1 PCTK2 PTCD2 TESK1 
ALPK3 CSNK1D GSG2 MAPK10 PCTK3 PTK2 TESK2 
AMHR2 CSNK1E GSK3A MAPK11 PDGFRA PTK2B TEX14 
ANKK1 CSNK1G1 GSK3B MAPK12 PDGFRB PTK6 TGFBR1 
ARAF CSNK1G2 GUK1 MAPK13 PDGFRL PTK7 TGFBR2 
ASB10 CSNK1G3 HCK MAPK14 PDIK1L PXK TIE1 
ATM CSNK2A1 HGS MAPK15 PDK1 RAF1 TK1 
ATMIN CSNK2A2 HIPK1 MAPK3 PDK2 RAGE TK2 
ATR DAK HIPK2 MAPK4 PDK3 RBKS TLK1 
AURKA DAPK1 HIPK3 MAPK6 PDK4 RET TLK2 
AURKAIP1 DAPK2 HIPK4 MAPK7 PDPK1 RFK TNIK 
AURKB DAPK3 HK1 MAPK8 PDXK RIOK1 TNK1 
AURKC DCAKD HK2 MAPK9 PFKL RIOK2 TNK2 
AXL DCK HK3 MAPKAPK2 PFKM RIOK3 TNNI3K 
BCKDK DCLK1 HKDC1 MAPKAPK3 PFKP RIPK1 TPD52L3 
BLK DCLK2 HUNK MAPKAPK5 PFTK1 RIPK2 TPK1 
BMP2K DCLK3 ICK MARK1 PFTK2 RIPK3 TPR 
BMP2KL DDR1 IGF1R MARK2 PGK1 RIPK4 TRAF3IP3 
BMPR1A DDR2 IGFN1 MARK3 PGK2 RIPK5 TRIB1 
BMPR1B DGKA IGSF22 MARK4 PHKG1 RNASEL TRIB2 
BMPR2 DGKB IHPK3 MAST1 PHKG2 ROCK1 TRIB3 
BMX DGKD IKBKB MAST2 PI4K2A ROCK2 TRRAP 
BRAF DGKE IKBKE MAST3 PI4K2B ROR1 TSKS 
BRSK1 DGKG IKBKG MASTL PI4KA ROR2 TSSK1B 
BRSK2 DGKH ILK MATK PI4KB ROS1 TSSK2 
BTK DGKI INSR MELK PICK1 RP2 TSSK3 
BUB1 DGKK INSRR MERTK PIK3AP1 RPS6KA1 TSSK4 
BUB1B DGKQ IP6K1 MET PIK3C2A RPS6KA2 TSSK6 
C19orf35 DGKZ IP6K2 MFHAS1 PIK3C2B RPS6KA3 TTBK1 
C1orf57 DGUOK IPMK MGC42105 PIK3C2G RPS6KA4 TTBK2 
C21orf7 DKFZp761P0423 IPPK MINK1 PIK3C3 RPS6KA5 TTC33 
C9orf95 DMPK IQCH MKNK1 PIK3CA RPS6KA6 TTK 
C9orf96 DNAJC6 IRAK1 MKNK2 PIK3CB RPS6KB1 TWF1 
C9orf98 DOK1 IRAK2 MLKL PIK3CD RPS6KB2 TWF2 
CALM1 DTYMK IRAK3 MORN1 PIK3CG RPS6KC1 TXK 
CALM2 DYRK1A IRAK4 MOS PIK3R3 RPS6KL1 TXNDC3 
CALM3 DYRK1B ITGB1BP3 MPP1 PIK3R4 RYK TXNDC6 
CAMK1 DYRK2 ITK MPP2 PIM1 SBK1 TYK2 
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Table 4.3A Continued 
CAMK1D DYRK3 ITPK1 MPP3 PIM2 SCGB2A1 TYRO3 
CAMK1G DYRK4 ITPKA MPP4 PIM3 SCYL1 UCK1 
CAMK2A EEF2K ITPKB MPP5 PINK1 SCYL2 UCK2 
CAMK2B EGFR ITPKC MPP6 PIP4K2A SCYL3 UCKL1 
CAMK2D EIF2AK1 JAK1 MPP7 PIP4K2B SGK1 UHMK1 
CAMK2G EIF2AK2 JAK2 MRC2 PIP4K2C SGK2 ULK1 
CAMK2N1 EIF2AK3 JAK3 MST1R PIP5K1A SGK269 ULK2 
CAMK4 EIF2AK4 KDR MST4 PIP5K1B SGK3 ULK3 
CAMKK1 EPHA1 KHK MUSK PIP5K1C SH3BP4 ULK4 
CAMKK2 EPHA10 KIAA0999 MVK PIP5KL1 SH3BP5 VRK1 
CAMKV EPHA2 KIAA1804 MYLK PKLR SH3BP5L VRK2 
CASK EPHA3 KIT MYLK2 PKM2 SHPK VRK3 
CCRK EPHA4 KSR1 MYLK3 PKMYT1 SIK1 WEE1 
CD2 EPHA5 KSR2 MYLK4 PKN1 SIK2 WNK1 
CDC2 EPHA6 LATS1 NADK PKN2 SKAP1 WNK2 
CDC2L1 EPHA7 LATS2 NAGK PKN3 SKP2 WNK3 
CDC2L5 EPHA8 LCK NEK1 PLK1 SLAMF6 WNK4 
CDC2L6 EPHB1 LIMK1 NEK10 PLK2 SLK XYLB 
CDC42BPA EPHB2 LIMK2 NEK11 PLK3 SMG1 YES1 
CDC42BPB EPHB3 LMTK2 NEK2 PLK4 SNRK YSK4 
CDC42BPG EPHB4 LMTK3 NEK3 PLXNA1 SNX16 ZAK 
CDC42SE2 EPHB6 LOC375133 NEK4 PLXNA2 SPHK1 ZAP70 
CDC7 ERBB2 LOC390877 NEK5 PLXNA3 SPHK2 ZC3HC1 
CDK10 ERBB3 LOC54103 NEK6 PLXNA4 SRC ZMYND8 
CDK2 ERBB4 LRPPRC NEK7 PLXNB1 SRMS  
CDK3 ERN1 LRRK1 NEK8 PLXNB2 SRPK1  
CDK4 ERN2 LRRK2 NEK9 PLXNB3 SRPK2  
CDK5 ETNK1 LTK NLK PLXNC1 SRPK3  
 
Table 4.3B List of PR genes validated by Transwell 
siRNA Targeting Genes Fold-Migration of SAMcell Fold-Migration of Transwell 
AAK1 1.24 1.25 
ACVR1 0.80 0.77 
ACVR2A 0.86 0.63 
ADCK4 0.72 0.31 
AKAP14 1.29 1.33 
ALPK1 1.13 1.35 
AMHR2 0.82 0.76 
ATK1 1.34 3.20 
BCKDK 1.14 1.29 
BMP2KL 1.11 1.04 
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Table 4.3B Continued 
C9ORF98 1.17 1.22 
CAMK2B 1.29 2.00 
CDC2L1 1.19 1.25 
CDC42BPG 1.12 1.29 
CDC7 1.11 1.48 
CKMT1B 1.23 1.43 
SRC 0.82 0.61 
CSNK1E 1.30 2.10 
CSNK2A2 1.31 1.53 
DGKD 1.10 1.87 
EIF2AK1 0.88 0.80 
EPHB2 1.34 1.78 
ERBB2 0.76 0.23 
ERBB4 0.78 0.67 
FASTK 0.90 0.80 
FLT1 0.78 0.70 
GUK1 0.85 0.49 
HK1 0.83 0.43 
HK2 0.88 0.78 
HK3 0.84 0.68 
HKDC1 1.19 1.40 
IGF1R 0.78 0.20 
IKBKE 1.12 1.28 
ILK 0.89 0.56 
IP6K1 0.90 0.56 
LY6G5B 0.89 0.70 
MAGI1 1.19 2.00 
MAGI2 1.18 2.10 
MAP2K1 0.90 0.80 
MAP3K1 0.79 0.61 
MAPK3 0.90 0.44 
MPP4 0.88 0.53 
MYLK 0.86 0.48 
NEK10 1.13 1.94 
NEK6 0.88 0.69 
NRBP1 0.86 0.74 
NUAK1 1.15 2.10 
OXSR1 1.16 1.26 
PACSIN2 1.13 1.20 
PAK2 0.85 0.50 
PAK4 0.89 0.79 
PANK2 1.25 1.34 
58 
 
Table 4.3B Continued 
PAPSS1 1.28 1.54 
PAPSS2 1.12 1.21 
PFTK2 0.76 0.42 
PGK2 0.81 1.10 
PIK3CA 0.82 0.38 
PIP5K1C 0.90 0.49 
PKN1 0.76 0.52 
PLK1 0.78 0.84 
PLXNB3 0.85 0.20 
PRKAA2 0.90 0.60 
PRKCDBP 1.27 1.09 
PRKCE 1.22 1.96 
PRKCH 0.75 0.36 
PSKH1 1.20 1.93 
RIOK2 0.81 0.72 
ROCK1 0.78 0.64 
RPS6KA4 1.21 1.20 
RYK 1.21 1.48 
SGK3 1.22 2.50 
SLK 1.11 1.26 
SPHK2 0.88 0.51 
CSK 1.31 1.81 
SRPK2 0.77 0.65 
STK40 0.83 0.80 
TAF1 0.75 0.45 
TESK2 0.88 0.80 
TLK2 0.85 0.91 
TNK1 0.81 0.80 
TPD52L3 0.78 0.71 
TRIB1 1.13 1.35 
TSSK3 0.86 0.41 
TWF2 1.24 1.24 
XYLB 1.18 1.20 
ZAK 1.13 1.29 
Note: Cut-off for SAMcell assay: Fold change<0.9 or >1.1; Cut-off for Transwell 
assay: Fold change <0.8 or >1.2; non-concordant behaviour in validation was 
highlight in green. 
 
Table 4.3C List of discordant genes interfered by proliferation or apoptosis 
siRNA Targeting Genes Fold-Proliferation Fold-Apoptosis 
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Table 4.3C Continued 
BMP2KL 1.23 1.03 
PGK2 0.91 1.27 
PLK1 0.52 5.61 
PRKCDBP 1.21 0.92 
TLK2 0.72 1.04 
Note: Cut-off for both assays: Fold change<0.8 or >1.2. 
 
Table 4.3D List of invasion screening results 
 
Table 4.3D Continued 
siRNA Targeting Genes Fold-Migration Fold-Invasion 
IGF1R 0.20 0.77 
PLXNB3 0.20 0.57 
ERBB2 0.23 0.41 
ADCK4 0.31 0.63 
PRKCH 0.36 0.57 
PIK3CA 0.38 0.80 
TSSK3 0.41 1.16 
PFTK2 0.42 0.83 
HK1 0.43 0.33 
MAPK3 0.44 1.13 
TAF1 0.45 0.55 
MYLK 0.48 0.59 
GUK1 0.49 0.83 
PIP5K1C 0.49 1.07 
PAK2 0.50 0.41 
SPHK2 0.51 1.11 
PKN1 0.52 0.43 
MPP4 0.53 1.13 
ILK 0.56 1.18 
IP6K1 0.56 0.71 
PRKAA2 0.60 0.80 
SRC 0.61 0.31 
MAP3K1 0.61 0.45 
ACVR2A 0.63 1.01 
ROCK1 0.64 0.44 
SRPK2 0.65 0.70 
ERBB4 0.67 0.51 
HK3 0.68 0.31 
NEK6 0.69 0.54 
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Table 4.3D Continued 
FLT1 0.70 0.41 
LY6G5B 0.70 1.07 
TPD52L3 0.71 1.11 
RIOK2 0.72 0.65 
NRBP1 0.74 0.61 
AMHR2 0.76 1.14 
ACVR1 0.77 0.76 
HK2 0.78 0.45 
PAK4 0.79 0.41 
EIF2AK1 0.80 0.78 
FASTK 0.80 0.45 
MAP2K1 0.80 0.72 
STK40 0.80 1.05 
TESK2 0.80 0.76 
TNK1 0.80 1.14 
PACSIN2 1.20 0.82 
RPS6KA4 1.20 0.91 
XYLB 1.20 0.87 
PAPSS2 1.21 1.29 
C9ORF98 1.22 1.56 
TWF2 1.24 0.82 
AAK1 1.25 1.63 
CDC2L1 1.25 1.99 
OXSR1 1.26 0.83 
SLK 1.26 0.84 
IKBKE 1.28 1.96 
BCKDK 1.29 0.87 
CDC42BPG 1.29 1.31 
ZAK 1.29 1.13 
AKAP14 1.33 1.1 
PANK2 1.34 1.03 
ALPK1 1.35 1.65 
TRIB1 1.35 1.06 
HKDC1 1.40 0.81 
CKMT1B 1.43 1.13 
CDC7 1.48 1.03 
RYK 1.48 1.11 
CSNK2A2 1.53 1.93 
PAPSS1 1.54 1.33 
EPHB2 1.78 1.83 
CSK 1.81 1.46 
DGKD 1.87 1.48 
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Table 4.3D Continued 
PSKH1 1.93 0.89 
NEK10 1.94 1.67 
PRKCE 1.96 0.94 
CAMK2B 2.00 1.03 
MAGI1 2.00 1.51 
CSNK1E 2.10 0.84 
MAGI2 2.10 1.67 
NUAK1 2.10 1.04 
SGK3 2.50 1.44 
AKT1 3.20 1.41 
Note: Cut-off for both assays: Fold change<0.8 or >1.2. 
 
4.4 Bioinformatics analysis to identify important genes 
 
After functional screening, we also performed bioinformatics analysis as complement.  
The first step of bioinformatics analysis was gene expression analysis, another 
powerful tool in understanding the mechanism of cancer metastasis. Such 
bioinformatics analysis helps identifying clinically important genes in terms of 
differential expression between normal and cancer samples. We downloaded publicly 
available microarray dataset (accession number: GSE6791) that studied the expression 
profile of 28 cervical samples (20 cancer samples and 8 normal samples)[115]. We 
took use of Rank Products[121], which is a simple, yet powerful, recently popular 
method to detect significant DEGs (differentially expressed genes). We computed all 
of the probe sets (more than 54,000) targeting the whole genome, using FDR (false 
discovery rate) of 0.05 and permutation of 100. Then we picked up the probe sets 
targeting the 47 migration- and invasion-significant genes and found 17 significant 
DEGs were identified out of 47 migration- and invasion-related genes from the 
aforementioned functional screening step (Table 4.4A). Among 17 significant DEGs, 
PAPSS1 has the discordant behavior, which represses migration and invasion 
activity[122] but results in higher expression in cancer samples. Finally, we 
discovered 16 genes that are important for cancer metastasis from both functional 




The second step of bioinformatics analysis was gene ontology (GO) analysis. We 
added annotation of biological processes and signalling pathways associated with 
cancer metastasis for each gene by use of AmiGO[116] and KEGG[117] database. 
Consequently, 7 out of 16 DEGs had no GO terms related to cancer metastasis (Table 
4.4C). 
 
The final step of bioinformatics analysis was PPIs (protein-protein interactions) 
analysis, which is important for the elucidation of cell regulatory mechanisms. We 
adopted prePPI database[118], which combines structural and non-structural 
interaction clues, to investigate the PPIs between these 16 genes. Consequently, 6 of 
them not only had no GO terms related to cancer metastasis, but also had no 
high-confidence interactions (Figure 4.4 & Table 4.4D). For high-confidence 
interactions, LR (likelihood ratio) should be more than 600 based on Bayesian 
classifier[123]. These 6 genes remained as the prospective metastasis-related genes, 
which required experimental validation. Importantly, the influences of the other 10 
well-characterized genes on cancer were all proved to be consistent with previous 





Figure 4.4 Bioinformatics analysis for kinase genes associated with cancer 
metastasis. Gray balls indicate the prospective metastasis-related kinase genes, 
chromatic balls indicate the well-characterized genes. Stronger associations are 
represented by thicker lines. Dash line means low confidence interaction. Solid line 
means high confidence interaction. The line highlighted in red means the proved 




Table 4.4A List of genes with significantly different expression levels in clinical 
samples   
Probe Set Number Gene Symbol FDR 
Relative Expression 
(Normal/Cancer) 
203935_at ACVR1 7.37E-06 0.306343 
230976_at C9ORF98 0.006698 1.917705 
1557666_s_at C9ORF98 0.008121 1.860398 
217736_s_at EIF2AK1 8.73E-05 0.337994 
202934_at HK2 0 0.26695 
225330_at IGF1R 0.033183 0.573851 
232859_s_at MAGI1 0.049932 1.741719 
202670_at MAP2K1 0 0.201356 
224823_at MYLK 0.007406 0.559965 
208875_s_at PAK2 0 0.207309 
208877_at PAK2 0 0.201757 
1559052_s_at PAK2 0.000392 0.401636 
208878_s_at PAK2 0.002724 0.450724 
208876_s_at PAK2 0.024318 0.556326 
209043_at PAPSS1 0.001268 0.41439 
203060_s_at PAPSS2 5.41E-05 2.292106 
203058_s_at PAPSS2 0.000732 2.050034 
204369_at PIK3CA 0 0.18829 
235980_at PIK3CA 0.002534 0.450777 
218764_at PRKCH 0.005392 0.471105 
218535_s_at RIOK2 0.005106 0.461254 
213044_at ROCK1 0.007998 0.47862 
214578_s_at ROCK1 0.018071 0.510435 
1558254_s_at SRPK2 7.75E-06 0.283112 
203182_s_at SRPK2 0.000147 0.348618 
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Table 4.4A Continued 
227205_at TAF1 0.005749 0.477768 
Note: Cut-off for FDR: <0.05; non-concordant expression pattern with the gene’s 
function was highlighted in green. 
 







Fold-Migration Fold-Invasion Reference 
Metastasis-promoting Genes 
MAP2K1 0.20 0.80 0.72 [125] 
HK2 0.27 0.78 0.45  
ACVR1 0.31 0.77 0.76 [126] 
PIK3CA 0.32 0.38 0.80 [127] 
SRPK2 0.32 0.65 0.70  
EIF2AK1 0.34 0.80 0.78  
PAK2 0.36 0.50 0.41 [128] 
RIOK2 0.46 0.72 0.65  
PRKCH 0.47 0.36 0.57 [129] 
TAF1 0.48 0.45 0.55 [130] 
ROCK1 0.50 0.64 0.44 [95] 
MYLK 0.56 0.48 0.59 [131] 
IGF1R 0.57 0.20 0.77 [132] 
Metastasis-repressing Genes 
MAGI1 1.67 2.00 1.51 [133] 
C9ORF98 1.89 1.22 1.56  
PAPSS2 2.02 1.21 1.29  
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Table 4.4C Continued 
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ALPK1 NM_025144 alpha-kinase 1   
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Table 4.4C Continued 
PRKCE NM_005400 
protein kinase C, 
epsilon 
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Note: 16 important DEGs significant in both functional screenings and expression 
analysis are highlighted in red. 
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Table 4.4D Continued 
MY
LK 
       575  - 20 
122
9 
- 205 62 - 
PA
K2 
        - - 
136
5 
11 667 59 17 
PAP
SS2 


















             140 79 
SRP
K2 
              - 
Note: LR (likelihood ratio) scores over 600 are considered as high-confident 
interactions. “-“ means no result in this database. Red means the proved 
interaction[124]. 
 
4.5 Experimental validation of prospective metastasis-related genes 
 
Besides migration and invasion, the influence of the 6 prospective genes on the cancer 
cells is also required to be studied in the context of proliferation, apoptosis and 
anoikis activities, considering their involvement in the process of metastasis as well. 
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When silencing prospective metastasis-promoting genes, including HK2, SRPK2, 
RIOK2 and EIF2AK1, cell motility (migration and invasion activities) and cell 
growth (proliferation activity) were down-regulated; whereas anti-survival traits 
(apoptosis, necrosis and anoikis activities) were up-regulated (Figure 4.5a). When 
silencing prospective metastasis-repressing genes, including C9ORF98 and PAPSS2, 
cell motility and cell growth were roughly up-regulated; whereas anti-survival traits 
were roughly down-regulated (Figure 4.5b). These functional validations confirm that 




Figure 4.5 Functional validation of prospective metastasis-related genes. Histograms 
showed functional activities of metastasis traits after silencing metastasis-promoting 
genes (a) or metastasis-repressing genes (b) in Hela. n=5.   
 
4.6 Summary of kinase screening 
 
We undertook a systematic and stringent screening approach that identified 11% of 
genes as regulators of migration and 5% of genes suppressing the cellular motility 
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potential. This proportion is higher than that of a whole genome screening[45], 
possibly owing to the focused nature of our siRNA library. This observation also 
supports the claim that the kinase genes play more important roles than the average 
level in cancer metastasis. Given that our results overlap less than 40% with the 
screening results of a breast epithelial normal cell line[44], mechanisms of regulating 
migration should be distinguishable between normal and cancer cells or between 
different types of tissues.  
 
Further implementation of invasion assay resulted in the identification of 47 genes 
capable of regulating cancer cell invasion, among which more than half of them have 
been characterized. These results suggest that more kinase genes might influence 
migration and invasion behaviors synergistically.  
 
Such functional analysis is more convincing than the conventional differential 
expression strategy, in which a candidate is chosen mainly based on its distinct 
expression level in disease samples relative to normal ones. However, we also used 
the differential expression strategy as complement to our screening results. 
  
Finally, we identified sixteen important genes for cancer metastasis, many of which, 
such as MAP2K1, PIK3CA, IGF1R, ROCK1 and MAGI1, are already successfully 
applied to clinical cancer therapy[96, 97, 133-135]. We also discovered six 
prospective metastasis-related genes. Through experimental validation, all of them are 
able to regulate cell growth and anti-survival capabilities besides cell motility. We 
believe that these findings provide new insight into the biological and therapeutical 




CHAPTER 5                                    
CONCLUSION 
 
First of all, we developed a novel on-chip method, SAMcell (self-assembled cell 
microarray), and set up a HTS platform to investigate functional genes regulating 
cancer metastasis on large scale. This method attracted attentions since it was 
published because of its unique features, such as low cost, simple operation, open 
system, and no cross-contamination.   
  
Secondly, we adopted this method to screen human genome miRNAs regulating 
cancer metastasis. We found 20% migratory miRNAs, which can help make an 
overall judgment of migratory miRNA distribution. We hypothesized a general 
regulation of miRNAs on cell migration and this seems to be another distinctive 
feature of miRNAs. After triple-round screenings for three phenotypes, including 
migration, invasion and apoptosis, we picked up the powerful gene miR-23b with the 
highest score in three rounds of screenings. miR-23b not only represses metastasis 
traits, but also has lower expression in cancer samples, suggesting that it has potential 
in cancer therapy.  
 
Thirdly, we adopted this method to screen human genome kinase genes regulating 
cancer metastasis. We found 11% migratory genes, suggesting that kinase genes 
contribute more to cancer metastasis than the average level. Our strategy was a good 
example for integration of functional screening and bioinformatics analysis, which 
makes the determination of important genes and therapeutical targets more convictive. 
Finally, we discovered and validated 6 prospective metastasis-related kinase genes, 
which can be new potential targets in cancer therapy.  
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APPENDIX A                                                    
SEQUENCE OF PRIMERS AND BINDING SITES 
                                                                                       
3’ UTR to be cloned Sequence of primers 
ADAMTS5 GCTCTAGACTCACTTACATAACTAAGCACT 
TGGAATTCCACTATTGGTCATGACAGATT 























































































cDNA for over-expression  
FZD7 CAAGCTTGAACCGCCTCGTCGCACTC  
CGGATCCGCCAAACCGCTTTCCACCC   
RRAS2 CGGCTAGCAGTCAGGCTGGGCTCTGT  
CGGAATTCGAGAAAGAGAAGATGAGGGCT  
MAP3K1 CGGAATTCTCTTTCTTTCGGAAGGTG   
GCTCTAGATCGTAAACCAGGAGACAAA   
PAK2 CGGGATCCTCATGTCTGATAACGGAGA   
GCTCTAGAAAGAGTAATAATTTTCATATACTAA 






Gene Wild type binding site Mutant binding site 
FZD7 GGCGATGTGAATCGTC GGCGGCACAGGTCGTC 
MAP3K1 TTTTTATGTGAATATGTT TTTTTGCACAGGTATGTT 
PAK2 AACAAATGTGAAAAAG   AACAGGCACAGGAAAG   
RRAS2 TTTTTAATGTGAATTTTT TTTTTGGCACAGATTTTT 
TGFBR2 ACAAAATGTGAAGGTG ACAAGGCACAGGGGTG 




APPENDIX B                                     
METHODS AND MATERIAL 
 
Cell culture, miRNA mimics and siRNA duplex 
Cell lines including Hela, HepG2, U2OS, MCF-7, PANC-1, and HCT 116 were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% FBS, 100 
units/ml penicillin and 0.1 mg/ml streptomycin under humidified conditions in 95% 
air and 5% CO2 at 37°C. HUVECs, which are donated from Professor Xingyu Jiang at 
National Center for Nanoscience and Technology, China, were cultured for three 
passages in ECM medium (ScienCell) containing 1% ECGS, 5% FBS, and 1% P/S. 
Transfection experiments were followed Lipofectamine™ 2000 (Invitrogen) 
transfection reagent protocol. 
 
All human miRNA mimics were obtained from the GenePharma (Shanghai, P.R. 
China). The Select Human Kinase siRNA Library (Ambion, Life Tech) was used and 
the repression efficiency was guaranteed by the provider. 
 
Transwell migration and invasion assay 
For migration assays, Hela cells were seeded into the upper chamber of a Transwell 
insert (pore size, 8µm; Costar) in 100μL serum-free medium per well. 600μL medium 
containing 10% serum was placed in the lower chamber to act as a chemoattractant. 
Non-migratory cells were removed from the upper chamber by scraping with a cotton 
bud. The cells remaining on the lower surface of the insert were fixed with 2% 
formaldehyde (Sigma) and stained by DAPI (Roche). For invasion assays, cells were 
seeded in a Matrigel (Bio-Rad)-coated chamber and were incubated at 37℃. 
 
Proliferation assay 
Hela transfected cells were seeded in a 12-well plate. After 48h of incubation, the 
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cells were trypsinized, and counted by hemocytometer measurement.  
 
Apoptosis and necrosis assay 
We used Annexin V-FITC Kit (Biosea Biotechnology Co. LTD) to detect apoptosis 
and necrosis of cells. Cells were identified by double labeling with Annexin V and PI 
assay. Cells are incubated with Annexin V solution for 30 minutes, followed by PI 
solution for 10 minutes. Cells at early apoptotic stage are stained by only Annexin V, 
and cells at late apoptotic stage are stained by both Annexin V and PI. Cells with 
necrosis were stained by only PI. 
 
Anoikis assay 
Cells with anoikis was detected by seeding 5.0 × 10
4
 cells in ultralow attachment 
plates (Corning). After 24 hr culture, cells were resuspended in 0.4% trypan blue 




Cells were seeded onto sterile cover slides and allowed to attach overnight. Cells were 
then fixed with 4% formaldehyde, permeabilized with 0.1% Triton X-100, and 
blocked in 2% BSA for 1 h at room temperature. The expression of E-cadherin or 
Vimentin was examined using their antibodies and visualized using Anti-Rabbit IgG 
(H+L), F (ab')2 Fragment (Alexa Fluor® 488 Conjugate) (Cell Signalling Tech.). 
Immunofluorescence was examined using an Olympus IX70 Confocal microscope. 





 293T cells were co-transfected with 200 ng of the indicated pGL3 firefly 
luciferase construct and 20ng of a pGL3 Renilla luciferase normalization control. In 
the meantime, the indicated miRNA expression plasmid or mimics was transfected. 
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The media was changed after 6 h, and luciferase activity was measured after 48 h 
using the dual luciferase reporter assay system (Promega, US).  
 
Immunoblotting 
Lysates were resolved by electrophoresis, transferred to a polyvinylidene difluoride 
membrane (Millipore), and probed with antibodies against MAP3K1 (Assay Designs), 
FZD7 (Abcam), TGFBR2 (CST), RRAS2 (Santa Cruz), PAK2 (CST), and GAPDH 
(Santa Cruz). The concentrations of the antibodies were 1:1000 diluted. 
 
Statistical analysis  
All results were expressed as means and n= derives from independent experiments. To 
determine whether data sets come from normal distribution, Shapiro-Wilk W-test and 
Kolmogorov–Smirnov Z-test were used (JMP9.0 Software). When comparing two 
groups, unpaired Student's t-tests (two-tailed) were used. For all tests, a P value <0.05 
was considered significant. Benjamini and Hochberg false discovery rate was used as 
a correction for multiple testing. * indicated P<0.05; ** indicated P<0.01; *** 
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